<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>y26624exv2w1.htm
<DESCRIPTION>EX-2.1: AGREEMENT AND PLAN OF MERGER
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;2.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>by and among</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MERCK &#038; CO., INC.,</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SPINNAKER ACQUISITION CORP.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>a wholly owned subsidiary of MERCK &#038; CO., INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SIRNA THERAPEUTICS, INC.</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Dated as of October&nbsp;30, 2006</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Page</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I The Merger; Closing; Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.1 The Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.2 Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">1.3 Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II Certificate of Incorporation and Bylaws of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.1 The Certificate of Incorporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">2.2 The Bylaws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III Officers and Directors of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.1 Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">3.2 Officers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV Effect of the Merger on Capital Stock; Exchange of Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.1 Effect on Capital Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.2 Exchange of Certificates for Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.3 Dissenters&#146; Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.4 Adjustments to Prevent Dilution</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.5 Treatment of Company Options and Warrants</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">4.6 Withholding Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V Representations and Warranties of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.1 Organization, Good Standing and Qualification; Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.2 Capitalization of the Company and its Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.3 Corporate Authority; Approval and Fairness</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.4 Consents and Approvals; No Violations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.5 Compliance with Laws; Licenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.6 No Default</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.7 Company Reports; Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.8 No Undisclosed Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.9 Absence of Certain Changes or Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.10 Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.11 Significant Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.12 Disclosure Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.13 Employee Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.14 Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.15 Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.16 No Payments Not Deductible Pursuant to Section&nbsp;280G</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.17 Real Property; Leasehold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.18 Environmental Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.19 Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.20 Takeover Statutes; Charter Provisions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.21 Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.22 Rights Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS<br>(cont.)</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Page</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">5.23 Third Party Supply</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI Representations and Warranties of Parent and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.1 Organization, Good Standing and Qualification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.2 Authority Relative to this Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.3 Consents and Approvals; No Violations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.4 Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.5 Disclosure Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.6 Availability of Funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.7 Brokers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">6.8 Access</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII Covenants of the Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.1 Operations of the Company&#146;s Business</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.2 Acquisition Proposals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.3 Stockholder Meeting; Proxy Material</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.4 Commercially Reasonable Efforts; Cooperation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.5 Access</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.6 Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.7 Public Announcements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.8 Employee Benefits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.9 Indemnification; Directors&#146; and Officers&#146; Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.10 Takeover Statutes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.11 Rights Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.12 Confidentiality</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.13 Resignations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">7.14 Stockholder Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII Conditions to Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.1 Conditions to the Obligations of the Company, Parent
and Merger Sub to Effect the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.2 Conditions to Obligations of Parent and Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">8.3 Conditions to Obligation of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.1 Termination by Mutual Consent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.2 Termination by Either Parent or the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.3 Termination by the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.4 Termination by Parent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">9.5 Effect of Termination and Abandonment; Termination Fee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ARTICLE X Miscellaneous and General</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.1 Non-Survival of Representations and Warranties and Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.2 Modification or Amendment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.3 Waiver of Conditions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS<br>(cont.)</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>Page</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.4 Counterparts; Signatures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.5 GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.6 Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.7 Entire Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.8 No Third Party Beneficiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.9 Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.10 Interpretation; Absence of Presumption</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.11 Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.12 Assignment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.13 Attorneys&#146; Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">10.14 Certain Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>AGREEMENT AND PLAN OF MERGER </B>(this &#147;<U>Agreement</U>&#148;), dated as of October&nbsp;30, 2006, by and
among MERCK &#038; CO., INC., a New Jersey corporation (&#147;<U>Parent</U>&#148;), SPINNAKER ACQUISITION CORP.,
a Delaware corporation and a wholly-owned subsidiary of Parent (&#147;<U>Merger Sub</U>&#148;), and SIRNA
THERAPEUTICS, INC., a Delaware corporation (the &#147;<U>Company</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RECITALS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the respective Boards of Directors of Parent, Merger Sub and the Company have
approved this Agreement, and deem it advisable and in the best interests of their respective
stockholders to consummate the merger of Merger Sub with and into the Company on the terms and
conditions set forth in this Agreement (the &#147;<U>Merger</U>&#148;) whereby each issued and outstanding
share of common stock, $0.01 par value, of the Company (the &#147;<U>Common Stock</U>&#148;), other than the
Common Stock owned by Parent, Merger Sub or the Company (or any of their respective direct or
indirect wholly owned subsidiaries) and the Dissenting Shares, shall be converted into the right to
receive the Merger Consideration as set forth in this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Parent, as the sole stockholder in Merger Sub, will approve the Merger and the
transactions contemplated hereby by written consent immediately following the execution hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Parent, Merger Sub and the Company, desire to make those representations, warranties,
covenants and agreements specified herein in connection with this Agreement; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, concurrently with the execution of this Agreement, and as a condition and inducement
to Parent&#146;s willingness to enter into this Agreement, certain stockholders of the Company have
entered into a Voting Agreement in the form attached hereto as Exhibit&nbsp;A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of and reliance upon the premises and the representations,
warranties, covenants and agreements contained herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be
legally bound hereby, Parent, Merger Sub and the Company agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>The Merger; Closing; Effective Time</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1. <U>The Merger</U>. Upon the terms and subject to the conditions set forth in this
Agreement, at the Effective Time, Merger Sub shall be merged with and into the Company and the
separate corporate existence of Merger Sub shall thereupon cease. The Company shall be the
surviving corporation in the Merger (sometimes hereinafter referred to as the &#147;<U>Surviving
Corporation</U>&#148;), and the separate corporate existence of the Company with all its rights,
privileges,
immunities, powers and franchises shall continue unaffected by the Merger, except as set forth
in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;II of this Agreement. The Merger shall have the effects specified in the Delaware
General Corporation Law, as amended (the &#147;<U>DGCL</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2. <U>Closing</U>. Unless otherwise mutually agreed in writing between Parent and the
Company, the closing for the Merger (the &#147;<U>Closing</U>&#148;) shall take place at the offices of
O&#146;Melveny &#038; Myers LLP, 275 Battery Street, San Francisco, California 94111-3305, at 5:00 P.M. local
time on the second (2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP>) business day (the &#147;<U>Closing Date</U>&#148;) following the day on
which the last to be satisfied or waived of the conditions set forth in Article&nbsp;VIII (other than
those conditions that by their nature are to be satisfied at the Closing, but subject to the
satisfaction or waiver of those conditions) shall be satisfied or waived in accordance with this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3. <U>Effective Time</U>. As soon as practicable following the Closing, Parent and the
Company will cause a Certificate of Merger (the &#147;<U>Certificate of Merger</U>&#148;) to be executed,
acknowledged and filed with the Secretary of State of the State of Delaware as provided in Section
251 of the DGCL. The Merger shall become effective at the time when the Delaware Certificate of
Merger has been duly filed with the Secretary of State of the State of Delaware or at such later
time as may be agreed by Parent and the Company in writing and specified in the Delaware
Certificate of Merger (the &#147;<U>Effective Time</U>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Certificate of Incorporation and Bylaws<BR>
of the Surviving Corporation</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1. <U>The Certificate of Incorporation</U>. The certificate of incorporation of the
Company shall be amended in its entirety to read as set forth as Exhibit&nbsp;B hereto and as so amended
shall be the certificate of incorporation of the Surviving Corporation (the &#147;<U>Charter</U>&#148;),
until thereafter amended as provided therein or by applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2. <U>The Bylaws</U>. The Bylaws of Merger Sub in effect at the Effective Time shall be
the Bylaws of the Surviving Corporation (the &#147;<U>Bylaws</U>&#148;), until thereafter amended as
provided therein or in accordance with the Charter and applicable Law.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Officers and Directors<BR>
of the Surviving Corporation</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1. <U>Directors</U>. Unless otherwise determined by Parent prior to the Effective Time,
the directors of Merger Sub at the Effective Time shall, from and after the Effective Time, be the
directors of the Surviving Corporation until their successors have been duly elected or appointed
and qualified or until their earlier death, resignation or removal in accordance with the Charter
and the Bylaws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2. <U>Officers</U>. Unless otherwise determined by Parent prior to the Effective Time, the
officers of Merger Sub at the Effective Time shall, from and after the Effective Time,
be the officers of the Surviving Corporation until their successors have been duly elected or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">appointed and qualified or until their earlier death, resignation or removal in accordance with the
Charter and the Bylaws.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Effect of the Merger on Capital Stock;<BR>
Exchange of Certificates</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1. <U>Effect on Capital Stock</U>. At the Effective Time, on the terms and subject to the
conditions herein set forth, as a result of the Merger and without any action on the part of the
holder of any capital stock of the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Merger Consideration</U>. Each share of the Common Stock issued and outstanding
immediately prior to the Effective Time (other than shares of Common Stock (i)&nbsp;owned by Parent or
any direct or indirect wholly-owned Subsidiary of Parent (collectively, the &#147;<U>Parent
Companies</U>&#148;), (ii)&nbsp;owned by the Company or any direct or indirect Subsidiary of the Company, or
(iii)&nbsp;shares of Common Stock (the &#147;<U>Dissenting Shares</U>&#148;) that are owned by stockholders (the
&#147;<U>Dissenting Stockholders</U>&#148;) properly exercising appraisal rights pursuant to Section&nbsp;262 of
the DGCL (each, an &#147;<U>Excluded Common Share</U>&#148; and collectively, &#147;<U>Excluded Common
Shares</U>&#148;)) shall be converted automatically into the right to receive $13.00 in cash, without
interest (the &#147;<U>Merger Consideration</U>&#148;). At the Effective Time, all shares of Common Stock
shall no longer be outstanding and shares of Common Stock shall be cancelled and retired and shall
cease to exist, and each certificate (a &#147;<U>Certificate</U>&#148;) formerly representing any such
shares of Common Stock (other than Excluded Common Shares) shall thereafter represent only the
right to the Merger Consideration and any Dissenting Shares shall thereafter represent only the
right to receive the applicable payments set forth in Section&nbsp;4.3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Cancellation of Shares</U>. Each share of Common Stock issued and outstanding
immediately prior to the Effective Time and owned by any of the Parent Companies, the Company or
any direct or indirect Subsidiary of the Company (in each case, other than such shares of Common
Stock that are held on behalf of third parties) shall, by virtue of the Merger and without any
action on the part of the holder thereof, cease to be outstanding, shall be cancelled and retired
without payment of any consideration therefor and shall cease to exist.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Merger Sub</U>. At the Effective Time, each share of common stock, par value $0.01
per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be
converted into one share of common stock, par value $0.01 per share, of the Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Employee Stock Purchase Plan</U>. Each right to purchase Common Stock (a
&#147;<U>Purchase Right</U>&#148;) outstanding for the Offering Period under the Company&#146;s Employee Stock
Purchase Plan ( the &#147;<U>ESPP</U>&#148;) that terminates at the Effective Time shall be cancelled and
each participant in the ESPP for that Offering Period shall be entitled to receive, within ten (10)
business days of the Effective Time, in lieu of any other consideration otherwise payable to
such participant under the ESPP with respect to such Purchase Right, an amount in cash equal to (a)
the Merger Consideration multiplied by (b)&nbsp;the number of whole and fractional shares of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Common
Stock that would have been issuable upon exercise of such Purchase Right had it been exercised at
the Effective Time and the participant purchased the maximum number of shares subject thereto using
the full amount of his or her accumulated payroll deductions to the ESPP for that Offering Period,
all such actions to have the same effect as described in Section&nbsp;12(b)(iii) of the ESPP. All
amounts payable pursuant to this Section&nbsp;4.1(d) shall be subject to and reduced by the amount of
any withholding that is required under applicable Tax Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2. <U>Exchange of Certificates for Shares</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Closing of the Company&#146;s Transfer Books</U>. At the Effective Time, (a)&nbsp;all shares of
Common Stock outstanding immediately prior to the Effective Time shall automatically be canceled
and retired and shall cease to exist, and all holders of certificates representing shares of Common
Stock that were outstanding immediately prior to the Effective Time shall cease to have any rights
as stockholders of the Company; and (b)&nbsp;the stock transfer books of the Company shall be closed
with respect to all shares of Common Stock outstanding immediately prior to the Effective Time. At
or after the Effective Time, there shall be no transfers on the stock transfer books of the Company
of the shares of Common Stock that were outstanding immediately prior to the Effective Time. If,
after the Effective Time, Certificates are presented to the Surviving Corporation or Parent for
transfer, they shall be cancelled and exchanged for a check in the proper amount pursuant to this
Article&nbsp;IV.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Paying Agent</U>. From time to time following the Effective Time, Parent shall
deposit, or shall cause to be deposited, with a paying agent appointed by Parent and approved in
advance by the Company (such approval not to be unreasonably withheld, conditioned or delayed) (the
&#147;<U>Paying Agent</U>&#148;), for the benefit of the holders of shares of Common Stock, cash for the
prompt payment of the Merger Consideration in exchange for shares of Common Stock outstanding
immediately prior to the Effective Time (other than Excluded Common Shares), deliverable upon due
surrender of the Certificates, pursuant to the provisions of this Article&nbsp;IV (such cash being
hereinafter referred to as the &#147;<U>Exchange Fund</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Payment Procedures</U>. Promptly after the Effective Time, the Surviving Corporation
shall cause the Paying Agent to mail to each holder of record of shares of Common Stock (i)&nbsp;a
letter of transmittal specifying that delivery shall be effected, and risk of loss and title to
Certificates shall pass, only upon delivery of Certificates to the Paying Agent and (ii)
instructions for use in effecting the surrender of the Certificates in exchange for the Merger
Consideration. Upon the surrender of a Certificate to the Paying Agent in accordance with the
terms of such letter of transmittal, duly executed, the holder of such Certificate shall be
entitled to receive in exchange therefor a check in the amount (after giving effect to any required
Tax withholdings) of (x)&nbsp;the number of shares of Common Stock represented by such Certificate
multiplied by (y)&nbsp;the Merger Consideration and the Certificate so surrendered shall forthwith be
cancelled. No interest will be paid or accrued on any amount payable upon due surrender of the
Certificates. In the event of a transfer of ownership of shares of Common Stock that is not
registered in the transfer records of the Company, a check for any cash to be paid upon due
surrender of the Certificate may be paid to such a transferee if the Certificate formerly
representing such shares of Common Stock is presented to the Paying Agent, accompanied by all
documents required to evidence and effect such transfer and to evidence that any applicable stock
transfer Taxes have been paid or are not applicable.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Termination of Exchange Fund</U>. Any portion of the Exchange Fund (including the
proceeds of any investments thereof) that remains unclaimed by the stockholders of the Company for
180&nbsp;days after the Effective Time shall be delivered to the Surviving Corporation. Any holders of
shares of Common Stock (other than Excluded Common Shares) who have not theretofore complied with
this Article&nbsp;IV shall thereafter look only to the Surviving Corporation for payment of (after
giving effect to any required Tax withholdings) the Merger Consideration, upon due surrender of
their Certificates, without any interest thereon. Notwithstanding the foregoing, none of Parent,
Merger Sub, the Company, the Paying Agent or any other Person shall be liable to any former holder
of shares of Common Stock for any amount properly delivered to a public official pursuant to
applicable abandoned property, escheat or similar Laws. If any Certificate shall not have been
surrendered prior to the date on which the applicable Merger Consideration would otherwise escheat
to or become the property of any Governmental Entity, any such Merger Consideration shall, to the
extent permitted by applicable Law, become the property of Parent, free and clear of all claims or
interest of any Person previously entitled thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Lost, Stolen or Destroyed Certificates</U>. In the event any Certificate shall have
been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming
such Certificate to be lost, stolen or destroyed and the posting by such Person of a bond in
customary amount and upon such terms as may be required by Parent as indemnity against any claim
that may be made against it with respect to such Certificate, the Paying Agent will issue a check
in the amount (after giving effect to any required Tax withholdings) of the number of shares of
Common Stock represented by such lost, stolen or destroyed Certificate multiplied by the Merger
Consideration upon due surrender of such lost, stolen or destroyed Certificate being surrendered.
Any affidavit of loss presented pursuant to this Article&nbsp;IV, to be deemed effective, must be in
form and substance reasonably satisfactory to the Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3. <U>Dissenters&#146; Rights</U>. Any Person who otherwise would be deemed a Dissenting
Stockholder shall not be entitled to receive the Merger Consideration with respect to the shares of
Common Stock owned by such Person unless and until such Person shall have failed to perfect or
shall have effectively withdrawn or lost such holder&#146;s right to dissent from the Merger under the
DGCL. Each Dissenting Stockholder shall be entitled to receive only the payment provided by
Section&nbsp;262 of the DGCL with respect to shares of Common Stock owned by such Dissenting
Stockholder. The Company shall give Parent (i)&nbsp;prompt notice of any written demands for appraisal,
attempted withdrawals of such demands and any other instruments served pursuant to applicable Law
received by the Company relating to stockholders&#146; rights of appraisal and (ii)&nbsp;the opportunity to
participate in all negotiations and proceedings with respect to demand for appraisal under the
DGCL. The Company shall not, except with the prior written consent of Parent, voluntarily make any
payment with respect to any demands for appraisals of Dissenting Shares, offer to settle or settle
any such demands or approve any withdrawal of any such demands.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4. <U>Adjustments to Prevent Dilution</U>. In the event that the Company changes the
number of shares of Common Stock, or securities convertible or exchangeable into or exercisable for
shares of Common Stock, issued and outstanding prior to the Effective Time as a result of a
reclassification, stock split (including a reverse stock split), stock dividend or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">distribution,
recapitalization, merger, subdivision, issuer tender or exchange offer, or other similar
transaction, the Merger Consideration shall be equitably adjusted to reflect such change.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5. <U>Treatment of Company Options and Warrants</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Effective as of the Effective Time each outstanding option to purchase shares of Company
Common Stock (each a &#147;<U>Company Stock Option</U>&#148;) that is outstanding and unexercised as of
immediately prior to the Effective Time shall be cancelled as of the Effective Time, whether then
vested or unvested, in exchange for the right to receive a cash payment, without interest, equal to
(i)&nbsp;the Merger Consideration, less the per-share exercise price of such option, multiplied by (ii)
the number of shares of Company Common Stock subject to such Company Stock Option. Such cash
payment shall be made to the holder of such option as soon as practicable after the Effective Time.
For purposes of clarity, no cash payment will be made with respect to any Company Stock Option so
cancelled with a per-share exercise price that equals or exceeds the Merger Consideration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company agrees to use its commercially reasonable efforts to cause all holders of the
Company&#146;s outstanding warrants (the &#147;<U>Warrants</U>&#148;) to fully exercise such Warrants prior to
the Effective Time. Parent and Company agree to take all actions necessary to comply with the
provisions of each of the Company&#146;s Warrants in accordance with their terms as in effect
immediately before the Effective Time, including, without limitation, Parent taking any necessary
actions or executing any necessary instruments to assume the Company&#146;s obligations thereunder,
issuing to the holder a new warrant consistent with the provisions of the Warrant as in effect
immediately before the Effective Time or making a cash payment consistent with the provisions of
the Warrant as in effect immediately before the Effective Time, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6. <U>Withholding Rights</U>. Parent, the Surviving Corporation or the Paying Agent shall
be entitled to deduct and withhold from the consideration otherwise payable pursuant to this
Agreement to any holder of shares of Common Stock, Company Stock Options, Purchase Rights or
Warrants, as applicable, such amounts as Parent, the Surviving Corporation or the Paying Agent, as
applicable, is required to deduct and withhold with respect to the making of such payment under the
Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), or any provision of state, local or
foreign Tax Law. To the extent that amounts are so withheld and paid over to the appropriate
taxing authority by Parent, the Surviving Corporation or the Paying Agent, such withheld amounts
shall be treated for all purposes of this Agreement as having been paid to the holder of the shares
of Common Stock, Company Stock Options, Purchase Rights or Warrants, as applicable, in respect of
which such deduction and withholding was made by such party.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Representations and Warranties of the Company</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in the Company&#146;s Annual Report on Form 10-K for the year ended December
31, 2005 and the Company&#146;s Quarterly Reports on Form 10-Q for the periods ended March&nbsp;31, 2006 and
June&nbsp;30, 2006, excluding information disclosed in the &#147;Risk Factors&#148; sections and &#147;Forward-Looking
Information&#148; sections of such reports filed prior to the date
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">hereof (it being understood that any
matter disclosed in the reports shall be deemed to be disclosed for all purposes of this Agreement
and the Company Disclosure Schedule, as long as the relevance of such disclosure is readily
apparent) and the applicable section of the disclosure schedule delivered by the Company to Parent
on the date hereof (the &#147;<U>Company Disclosure Schedule</U>&#148;) (it being understood that any matter
disclosed pursuant to any section or subsection of the Company Disclosure Schedule shall be deemed
to be disclosed for any other section or subsection so long as the applicability to such other
section or subsection is readily apparent from the face of such disclosure), the Company hereby
represents and warrants to Parent and Merger Sub as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1. <U>Organization, Good Standing and Qualification; Subsidiaries</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each of the Company and its Subsidiaries is a corporation or other legal entity duly
organized, validly existing and in good standing (with respect to jurisdictions that recognize the
concept of good standing) under the Laws of the jurisdiction of its incorporation or organization
and has all requisite corporate or other power and authority to own, lease and operate its
properties and assets and to carry on its businesses as now being conducted and is qualified to do
business and is in good standing (with respect to jurisdictions that recognize the concept of good
standing) as a foreign corporation in each jurisdiction where the ownership, leasing or operation
of its properties or assets or conduct of its business requires such qualification, except where
the failure to be so qualified or in good standing (with respect to jurisdictions that recognize
the concept of good standing) or to have such power or authority, does not have, and would not
reasonably be expected to have, either individually or in the aggregate, a Company Material Adverse
Effect. Neither the Company nor any of its Subsidiaries is in violation of its organizational or
governing documents, except for such violations that do not have, and would not reasonably be
expected to have, either individually or in the aggregate, a Company Material Adverse Effect. The
Company has heretofore delivered or made available to Parent accurate and complete copies of the
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and other
organizational documents, as currently in effect, of the Company and each of its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Section&nbsp;5.1(b)</U> of the Company Disclosure Schedule contains a complete and accurate
list of the name and jurisdiction of organization of each Subsidiary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2. <U>Capitalization of the Company and its Subsidiaries</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The authorized capital stock of the Company consists of 125,000,000 shares of capital
stock, including 120,000,000 shares of Common Stock, of which 72,960,367 shares of Common Stock
were issued and outstanding as of the close of business on October&nbsp;27,
2006, 5,000,000 shares of Preferred Stock, par value $0.01 per share (&#147;<U>Preferred
Stock</U>&#148;), none of which Preferred Stock is outstanding (including 200,000 shares of Series&nbsp;AA
Junior Preferred Stock, par value $0.01 per share, reserved for issuance in connection with the
exercise of preferred stock purchase rights (the &#147;<U>Company Rights</U>&#148;) issued pursuant to that
certain Rights Agreement, dated as of November&nbsp;22, 2000, between the Company and American Stock
Transfer &#038; Trust Company, as Rights Agent, as amended by Amendment No.&nbsp;1 thereto, dated February
11, 2003 (the &#147;<U>Rights Agreement</U>&#148;)). All of the outstanding shares of Common Stock have
been duly authorized and validly issued and are fully paid and nonassessable. The
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company has no
shares of Common Stock or Preferred Stock reserved for or otherwise subject to issuance, except
that as of the close of business on October&nbsp;27, 2006, there were 6,656,963 shares of the Common
Stock subject to issuance pursuant to options outstanding under the plans of the Company identified
in <U>Section&nbsp;5.2</U> of the Company Disclosure Schedule or the Company Stock Plans and 10,382,372
shares of the Common Stock subject to issuance pursuant to the Warrants. The name of the holder of
each Company Stock Option, the exercise price of such Company Stock Option and the aggregate number
of shares of Common Stock subject to such Company Stock Option are set forth on Section&nbsp;5.2(a) of
the Company Disclosure Schedule. 449,344 shares of the Common Stock are reserved for issuance
pursuant to the ESPP, of which 25,000 Shares will be issued at the conclusion of the Offering
Period ending October&nbsp;31, 2006. Each of the outstanding shares of capital stock or other ownership
interests of each of the Company&#146;s Subsidiaries is duly authorized, validly issued, fully paid and
nonassessable and owned by the Company or a direct or indirect wholly owned Subsidiary of the
Company, in each case free and clear of any Lien. There are no registration rights or preemptive
or other outstanding rights, options, warrants, conversion rights, stock appreciation rights,
redemption rights, repurchase rights, agreements, arrangements, calls, commitments or rights of any
kind which obligate the Company or any of its Subsidiaries to register, issue or sell any shares of
capital stock or other securities of the Company or any of its Subsidiaries or any securities or
obligations convertible or exchangeable into or exercisable for, or giving any Person a right to
subscribe for or acquire from the Company or any of its Subsidiaries, any securities of the Company
or any of its Subsidiaries, and no securities or obligations evidencing such rights are issued or
outstanding. The Company does not have outstanding any bonds, debentures, notes or other
obligations the holders of which have the right to vote (or which are convertible into or
exercisable for securities having the right to vote) with the stockholders of the Company on any
matter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As of the date of this Agreement, there are outstanding and unexercised Warrants to
purchase 10,382,372 shares of Common Stock. <U>Section&nbsp;5.2(b)</U> of the Company Disclosure
Schedule identifies for each Warrant, (i)&nbsp;the name of the holder of the Warrant as of the date of
this Agreement; (ii)&nbsp;the date on which such Warrant was granted; (iii)&nbsp;the exercise price per share
of the Warrant; (iv)&nbsp;the number of shares covered by the Warrant; (v)&nbsp;the number of shares of
Common Stock as to which such Warrant had vested at such date; (vi)&nbsp;the applicable vesting schedule
for such Warrant and whether the exercisability or vesting of the Warrant will be accelerated in
any way by the Merger or the transactions contemplated hereby; (vii)&nbsp;whether such Warrant was
issued in connection with the performance of services and (viii)&nbsp;the date on which the Warrant
expires. All of the shares of Common Stock subject to the issuance pursuant to the Warrants, upon
issuance prior to or at the Effective Time on terms and conditions specified in the instruments
pursuant to which they are issuable, will be duly authorized, validly
issued, fully paid, nonassessable and free of preemptive rights. The Company has made
available to Parent complete and correct copies of all Warrants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There are no voting trusts or other agreements or understandings to which the Company or
any of its Subsidiaries is a party with respect to the voting of any of the capital stock of the
Company or any of the Subsidiaries. Other than as set forth on <U>Section&nbsp;5.2</U> of the Company
Disclosure Schedule, none of the Company or any of its Subsidiaries is obligated under any
registration rights or similar agreements to register any shares of capital stock of the Company or
any of its Subsidiaries on behalf of any Person.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Since October&nbsp;12, 2004, no milestone event as described in the Sale Agreement among the
Company, Skinetics Biosciences, Inc. and the sellers described therein has occurred and no fact,
event or circumstance has occurred that would reasonably be expected to cause such a milestone
event to occur.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Prior to the date hereof, the Company has taken all actions with respect to the ESPP as
are necessary to provide that the ESPP shall terminate prior to the Effective Time, that no Person
will have any right to purchase Common Stock under the ESPP after the Effective Time and that no
more than 20,000 shares of Common Stock may be issued in the aggregate with respect to any Offering
Period (as defined in the ESPP) that begins after the date hereof (but prior to the Effective
Time). The Company has provided to Parent written evidence of each of the foregoing. Any Offering
Period (as defined in the ESPP) in effect immediately prior to the Effective Time will terminate at
the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3. <U>Corporate Authority; Approval and Fairness</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company has all requisite corporate power and authority and has taken all corporate
action necessary in order to execute, deliver and perform its obligations under this Agreement,
subject only to adoption of this Agreement by its stockholders by the Company Requisite Vote, and
to consummate the Merger. The affirmative vote of a majority of the outstanding shares of Common
Stock (such affirmative vote, the &#147;<U>Company Requisite Vote</U>&#148;), is the only vote of the
holders of any class or series of capital stock or securities of the Company necessary to adopt,
approve or authorize this Agreement, the Merger and the other transactions contemplated hereby.
This Agreement is a valid and binding agreement of the Company enforceable against the Company in
accordance with its terms except for (i)&nbsp;the effect of any applicable bankruptcy, insolvency,
reorganization, moratorium and similar laws relating to or affecting the rights of creditors
generally and (ii)&nbsp;the effect of equitable principles of general application.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Board of Directors of the Company (the &#147;<U>Company Board</U>&#148;) at a duly held meeting
has unanimously (i)&nbsp;approved the execution, delivery and performance of this Agreement and the
consummation by the Company of the transactions contemplated hereby, including the Merger; (ii)
received the oral opinion of its financial advisors, Goldman, Sachs &#038; Co., to be subsequently
confirmed in writing, to the effect that as of the date of this Agreement and based upon and
subject to the assumptions and limitations set forth therein, the Merger Consideration to be
received by the holders of shares of Common Stock (other than the Parent Companies) pursuant to
this Agreement is fair from a
financial point of view to such holders and such opinion will be included in the Proxy
Materials; (iii)&nbsp;determined that this Agreement and the transactions contemplated hereby are in the
best interests of the holders of shares of Common Stock, and declared it advisable, to enter into
this Agreement; (iv)&nbsp;resolved to recommend adoption of this Agreement, the Merger and the other
transactions contemplated hereby to the holders of shares of Common Stock; and (v)&nbsp;directed that
such matters be submitted for consideration of the holders of shares of Common Stock for their
adoption (the matters described in clauses (i), (iii), (iv)&nbsp;and (v), the &#147;<U>Recommendation</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4. <U>Consents and Approvals; No Violations</U>. No filing with or notice to, and no
permit, authorization, registration, consent or approval of, any court or tribunal or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">administrative, governmental or regulatory body, agency, authority or other entity (a
&#147;<U>Governmental Entity</U>&#148;) is required on the part of the Company or any of its Subsidiaries
for the execution, delivery and performance by the Company of this Agreement or the consummation by
the Company of the transactions contemplated hereby, except (i)&nbsp;as set forth in <U>Section&nbsp;5.4</U>
of the Company Disclosure Schedule; (ii)&nbsp;pursuant to the applicable requirements of the Securities
Act of 1933, as amended (including the rules and regulations promulgated thereunder the
&#147;<U>Securities Act</U>&#148;) and the Securities Exchange Act of 1934, as amended (including the rules
and regulations promulgated thereunder the &#147;<U>Exchange Act</U>&#148;); (iii)&nbsp;the filing of the
Certificate of Merger pursuant to the DGCL; (iv)&nbsp;compliance with any applicable requirements of the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the &#147;<U>HSR Act</U>&#148;); (v)
compliance with any applicable requirements of laws, rules and regulations in other foreign
jurisdictions governing antitrust or merger control matters; or (vi)&nbsp;where the failure to obtain
such permits, authorizations, consents or approvals or to make such filings or give such notice
does not have and would not reasonably be expected to have, either individually or in the
aggregate, a Company Material Adverse Effect. Neither the execution, delivery and performance of
this Agreement by the Company nor the consummation by the Company of the transactions contemplated
hereby will: (A)&nbsp;conflict with or result in any breach, violation or infringement of any provision
of the respective certificate of incorporation or Bylaws (or similar governing documents) of the
Company or of any its Subsidiaries; (B)&nbsp;result in a breach, violation or infringement of, or
constitute (with or without due notice or lapse of time or both) a default (or give rise to the
creation of any Lien or any right of termination, amendment, cancellation or acceleration) under,
any of the terms, conditions or provisions of any note, bond, mortgage, indenture, lease, license,
contract, agreement or other instrument or obligation, whether written or oral (each a
&#147;<U>Contract</U>&#148;), to which the Company or any of its Subsidiaries is a party or by which any of
them or any of their respective properties or assets may be bound; (C)&nbsp;change the rights or
obligations of any party under any Contract; or (D)&nbsp;violate or infringe any order, writ,
injunction, judgment, arbitration award, agency requirement, decree, law, statute, ordinance, rule
or regulation, concession, franchise, permit, license or other governmental authorization or
approval (each a &#147;<U>Law</U>&#148;) applicable to the Company or any of its Subsidiaries or any of
their respective properties or assets, except in the case of (B), (C)&nbsp;or (D)&nbsp;for breaches,
violations, infringements, defaults or changes which would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5. <U>Compliance with Laws; Licenses</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The businesses of each of the Company and its Subsidiaries have been conducted in
accordance with federal, state, local or foreign Laws, including Laws enforced by the United States
Food and Drug Administration (&#147;<U>FDA</U>&#148;) or any similar state or foreign regulatory or
Governmental Entities in all material respects. The Company is not debarred under the Federal
Food, Drug and Cosmetic Act or otherwise excluded from or restricted in any manner from
participation in, any government program related to pharmaceutical products and, to its Knowledge,
does not employ or use the services of any individual or entity that is or, during the time when
such individual or entity was employed by or providing services to the Company or any of its
Subsidiaries, was debarred or otherwise excluded or restricted. No investigation or review by any
Governmental Entity with respect to the Company or any of its Subsidiaries is pending or, to the
Knowledge of the Company, threatened, nor has any Governmental Entity indicated an intention to
conduct the same, except for such investigations
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or reviews that would not have, and would not
reasonably be expected to have, either individually or in the aggregate, a Company Material Adverse
Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company and its Subsidiaries each has all governmental permits, licenses, franchises,
variances, exemptions, orders issued or granted by a Governmental Entity and all other
authorizations, consents and approvals issued or granted by a Governmental Entity
(&#147;<U>Licenses</U>&#148;) necessary to conduct the business of the Company and its Subsidiaries as
presently conducted, except those the absence of which would not have, and would not reasonably be
expected to have, either individually or in the aggregate, a Company Material Adverse Effect (the
&#147;<U>Material Licenses</U>&#148;). There is not pending or, to the Knowledge of the Company, threatened
before any Governmental Entity any proceeding, notice of violation, order of forfeiture or
complaint or investigation against the Company or any of its Subsidiaries relating to any Material
License, in each case, except as would not have, and would not reasonably be expected to have,
either individually or in the aggregate, a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each of the products, product candidates and active pharmaceutical ingredients of the
Company and its Subsidiaries is being, and at all times since January&nbsp;1, 2003, as applicable, has
been, developed, tested, manufactured, handled, distributed, and stored, as applicable, in
compliance in all material respects with all applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company has filed and made available to Parent each annual report filed by any of the
Company and its Subsidiaries with the FDA and any similar state or foreign regulatory or
Governmental Entity with respect to any products of the Company or its Subsidiaries or any similar
state or foreign Governmental Entity since January&nbsp;1, 2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Neither the Company nor any of its Subsidiaries is subject to any pending or, to the
Knowledge of the Company, threatened, investigation by: (A)&nbsp;the FDA pursuant to its &#147;Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities,&#148; set forth in 56 Fed. Reg. 46191
(September&nbsp;10, 1991); (B)&nbsp;Department of Health and Human Services Officer of Inspector General or
Department of Justice pursuant to the Federal Anti-Kickback Statute (42. U.S.C. Section&nbsp;1320a-7(b))
or the Federal False Claims Act (31 U.S.C. Section&nbsp;3729 <I>et seq</I>.); or (C)&nbsp;any equivalent statute of
any country in the European Union. Neither the Company nor any of its Subsidiaries, nor, to the
Knowledge of the Company, (1)&nbsp;any officer or employee of the Company or any of its Subsidiaries,
(2)&nbsp;any authorized agent of the Company or any of its
Subsidiaries or (3)&nbsp;any principal investigator or sub-investigator of any clinical
investigation sponsored by the Company or any of its Subsidiaries has, in the case of each of (1)
through (3)&nbsp;on account of actions taken for or on behalf of the Company or any of its Subsidiaries,
been convicted of any crime under 21 U.S.C. Section&nbsp;335a(a) or any similar state or foreign Law or
under 21 U.S.C. Section&nbsp;335a(b) or any similar state or foreign Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Since January&nbsp;1, 2003, no clinical trial of a product of the Company or any of its
Subsidiaries has been suspended, put on hold or terminated prior to completion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;There are no third party manufacturers or suppliers of the Company&#146;s products, product
candidates and active pharmaceutical ingredients.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;The Company has made available to Parent (A)&nbsp;complete and accurate copies of each
Investigational New Drug application (&#147;<U>IND</U>&#148;), and each similar state or foreign regulatory
filing made by or on behalf of the Company and its Subsidiaries, including all supplements and
amendments, (B)&nbsp;any correspondence received from the FDA and similar state and foreign Governmental
Entities that concerns a product of the Company or its Subsidiaries covered by an IND described in
clause (A)&nbsp;above, and (C)&nbsp;all existing written records relating to all material discussions and all
meetings between the Company or its Subsidiaries and the FDA or similar foreign regulatory or
Governmental Entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Since January&nbsp;1, 2003, the clinical trials, animal studies and other preclinical tests
conducted by or on behalf of the Company or its Subsidiaries were, and if still pending, are, being
conducted in all material respects in accordance with all experimental protocols, informed
consents, procedures and controls of the Company and its Subsidiaries and applicable FDA
requirements including, but not limited to, good clinical practice and good laboratory practice
regulations. Neither the Company nor any of its Subsidiaries has received any written notice from
the FDA or any other regulatory or Governmental Entity requiring the material modification of any
animal study, preclinical study or clinical trial conducted by or on behalf of the Company or any
Subsidiary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Neither the Company nor any of its Subsidiaries or its Affiliates, nor, to the Knowledge
of the Company, any of its third party suppliers (with respect to a facility producing materials
for the Company or its Subsidiaries) has received a FDA Form&nbsp;483 notice or similar notice with
respect to any production plants. A true and correct copy of any item set forth on Section&nbsp;5.5(j)
of the Company Disclosure Schedule has been made available to Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;Neither the Company nor its Subsidiaries has knowingly or willfully solicited, received,
paid or offered to pay any remuneration, directly or indirectly, overtly or covertly, in cash or
kind for the purpose of making or receiving any referral which violated any applicable
anti-kickback or similar Law, including the Federal Anti-Kickback Statute, or any applicable state
anti-kickback Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;The Company and its Subsidiaries have not failed to comply with any applicable security
and privacy standards regarding protected health information under the Health Insurance Portability
and Accountability Act of 1996, including the regulations promulgated thereunder or any applicable
state privacy Laws, except for any such failures to
comply, that have not had, and would not reasonably be expected to have, either individually
or in the aggregate, a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;With respect to all third party manufacturers and suppliers of key raw materials used by
the Company or its Subsidiaries (each a &#147;<U>Third Party Manufacturer</U>&#148;), the Company has
inspected all Third Party Manufacturers and to its Knowledge, each such Third Party Manufacturer:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) has complied and is complying in all material respects with all applicable Laws,
including Laws enforced by the FDA and any similar state or foreign regulatory or
Governmental Entities;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) has all permits to perform its obligations as Third Party Manufacturer and all
such permits are in full force and effect, except as either individually or in the
aggregate, has not had, and would not reasonably be expected to have, a Company Material
Adverse Effect; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) has not been debarred under the Federal Food, Drug and Cosmetic Act or similar
law of any other jurisdiction or otherwise excluded from or restricted in any manner from
participation in, any government program related to pharmaceutical products and does not
employ or use the services of any individual or entity that is or, during the time when such
person or entity was providing services as a Third Party Manufacturer to the Company or any
of its Subsidiaries, was debarred or otherwise excluded or restricted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;All inventory of key starting material, reagents, active pharmaceutical ingredient and/or
product have been manufactured, handled, stored and distributed in accordance with applicable Laws,
including good manufacturing practice in all material respects. The Company has sufficient
inventory of key starting materials, reagents, active pharmaceutical ingredients and/or products in
order to operate business in the ordinary course.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.6. <U>No Default</U>. Neither the Company nor any of its Subsidiaries is in default or
violation (and no event has occurred which with notice or the lapse of time or both would
constitute a default or violation) of any term, condition or provision of (i)&nbsp;its certificate of
incorporation or Bylaws (or similar governing documents), (ii)&nbsp;any Contract to which the Company or
any of its Subsidiaries is now a party or by which any of them or any of their respective
properties or assets may be bound, or (iii)&nbsp;any Law applicable to the Company, any of its
Subsidiaries or any of their respective properties or assets, except in the case of clause (ii)&nbsp;or
(iii)&nbsp;of this sentence for violations, breaches or defaults that have not had, and would not
reasonably be expected to have, either individually or in the aggregate, a Company Material Adverse
Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7. <U>Company Reports; Financial Statements</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company has made available to Parent each registration statement, report, proxy
statement or information statement prepared by it since December&nbsp;31, 2005, including, without
limitation, (i)&nbsp;the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2005 and
(ii)&nbsp;the Company&#146;s Quarterly Reports on Form 10-Q for the periods
ended March&nbsp;31, 2006 and June&nbsp;30, 2006 (the &#147;<U>Balance Sheet Date</U>&#148;), each in the form
(including any amendments thereto) filed with the Securities and Exchange Commission
(&#147;<U>SEC</U>&#148;). The Company has filed and furnished all forms, statements, reports and documents
required to be filed or furnished by it with the SEC pursuant to applicable securities statutes,
regulations, policies and rules since January&nbsp;1, 2003 (the forms, statements, reports and documents
filed since January&nbsp;1, 2003, or those filed subsequent to the date of this Agreement, and as
amended, the &#147;<U>Company Reports</U>&#148;). The Company Reports were prepared in all material
respects in accordance with the applicable requirements of the Securities Act and the Exchange Act
and complied in all material respects with the then applicable accounting standards. As of their
respective dates (and, if amended, as of the date of such amendment), the Company Reports did not,
and any Company Reports filed with the SEC subsequent to the date of this Agreement
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">will not,
contain any untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements made therein, in light of the circumstances in
which they were made, not misleading. There are no outstanding comment letters or requests for
information from the SEC with respect to any Company Report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the consolidated balance sheets included in or incorporated by reference into the
Company Reports (including the related notes and schedules) filed prior to the date of this
Agreement fairly presents, and, if filed after the date of this Agreement, will fairly present, in
each case, in all material respects, the consolidated financial position of the Company or any
other entity included therein and their respective Subsidiaries, as of its date, and each of the
consolidated statements of operations, cash flows and of changes in stockholders&#146; equity included
in or incorporated by reference into the Company Reports (including any related notes and
schedules) fairly presents, and, if filed after the date of this Agreement, will fairly present, in
all material respects, the results of operations, retained earnings and changes in financial
position, as the case may be, of the Company or any other entity included therein and their
respective Subsidiaries for the periods set forth therein (subject, in the case of unaudited
financial statements, to notes and normal year-end audit adjustments that will not be material in
amount or effect), in each case in accordance with U.S. generally accepted accounting principles
(&#147;<U>GAAP</U>&#148;) consistently applied during the periods involved, except as may be noted therein.
The Company: (i)&nbsp;maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15(e) and
15d-15(e) of the Exchange Act) designed to ensure that material information required to be
disclosed by the Company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules
and forms and is accumulated and communicated to the Company&#146;s management as appropriate to allow
timely decisions regarding required disclosure and (ii)&nbsp;has disclosed, based on its most recent
evaluation of such disclosure controls and procedures prior to the date hereof, to the Company&#146;s
auditors and the audit committee of the Company Board (A)&nbsp;any significant deficiencies and material
weaknesses in the design or operation of internal controls over financial reporting could adversely
affect in any material respect the Company&#146;s ability to record, process, summarize and report
financial information and (B)&nbsp;any fraud, whether or not material, that involves management or other
employees who have a significant role in the Company&#146;s internal controls over financial reporting.
The Company has made available to Parent a summary of any such disclosure made by management to the
Company&#146;s auditors and audit committee since the Balance Sheet Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8. <U>No Undisclosed Liabilities</U>. There are no liabilities of the Company or any of
its Subsidiaries, whether accrued, absolute, fixed or contingent, other than those: (i)&nbsp;set forth
or adequately provided for in the condensed consolidated balance sheet of the Company and its
Subsidiaries included in the June&nbsp;30, 2006 Form 10-Q of the Company; (ii)&nbsp;incurred since the
Balance Sheet Date in the ordinary course of business consistent with past practice that have not
had, or which would not reasonably be expected to have either individually or in the aggregate, a
Company Material Adverse Effect; (iii)&nbsp;incurred under this Agreement or in connection with the
transactions contemplated hereby or (iv)&nbsp;which would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9. <U>Absence of Certain Changes or Events</U>. Since the Balance Sheet Date, there has
not been any Company Material Adverse Effect or any event, occurrence, discovery,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">effect,
violation, inaccuracy, circumstance, state of facts or development which has had, or would
reasonably be expected to have or result, either individually or in the aggregate, in a Company
Material Adverse Effect, and since the Balance Sheet Date and through the date hereof, the Company
and its Subsidiaries have conducted their business in the ordinary course consistent with past
practice, and neither the Company nor any of its Subsidiaries has taken or authorized or agreed to
the taking of any action referred to in Sections&nbsp;7.1(a)(i), 7.1(a)(vi) 7.1(a)(vii), 7.1(a)(viii),
7.1(a)(ix), 7.1(a)(xi), 7.1(a)(xii), 7.1(a)(xiii) and 7.1(a)(xiv).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10. <U>Litigation</U>. There is no civil, criminal or administrative suit, claim, inquiry,
action, proceeding or investigation (each an &#147;<U>Action</U>&#148;) pending or, to the Knowledge of the
Company, threatened in writing against the Company or any of its Subsidiaries or any of their
respective properties or assets, or any executive officer or director of the Company or any of its
Subsidiaries (in their capacity as an executive officer or director), or which would make the
Company or any of its Subsidiaries a party in such Action, which, in any such case, if adversely
determined or concluded, (i)&nbsp;involves an amount in controversy in excess of $250,000 or (ii)&nbsp;has
had or would reasonably be expected to have, either individually or in the aggregate, a Company
Material Adverse Effect. Neither the Company nor any of its Subsidiaries is subject to any
outstanding order, writ, injunction or decree. There is no outstanding order against the Company
or any of its Subsidiaries or by which any property, asset or operation of the Company or any of
its Subsidiaries is bound. To the Knowledge of the Company, as of the date of this Agreement,
neither the Company, any Subsidiary, nor any officer, director or employee of the Company or any
such Subsidiary is under investigation by any Governmental Entity relating to the conduct of the
Company&#146;s or any such Subsidiary&#146;s business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11. <U>Significant Contracts</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;True and correct copies have been made available to Parent of all Contracts to which the
Company or any of its Subsidiaries is a party which are in effect as of the date hereof and fall
within any of the following categories: (i)&nbsp;any Contract required to be disclosed in a Company
Report; (ii)&nbsp;any Contract relating to indebtedness for borrowed money or any financial guaranty;
(iii)&nbsp;any Contract that limits the ability of the Company, its Subsidiaries or any of their
Affiliates to conduct or compete in any activity or business or in any geographic area; (iv)&nbsp;any
Contract that involves anticipated future expenditures by the Company or any of its Subsidiaries of
more than $250,000; (v)&nbsp;any joint venture, manufacturing, research (other than &#147;material transfer
agreements&#148;), supply, collaboration or partnership Contract; (vi)&nbsp;any Contract
for the lease or purchase of real property; (vii)&nbsp;any Contract with any director, officer or
Affiliate of the Company or any of its Subsidiaries; and (viii)&nbsp;any Contract relating to the
acquisition, development, license, transfer or disclosure of Intellectual Property which Contract
is material to the business of the Company or any of its Subsidiaries other than &#147;material transfer
agreements&#148; in customary form entered into in the ordinary course of business (collectively and
with the IP Agreements, &#147;<U>Significant Contracts</U>&#148;). <U>Section&nbsp;5.11(a)</U> of the Company
Disclosure Schedule lists each Significant Contract of the Company or any of its Subsidiaries as of
the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the Significant Contracts are valid agreements and enforceable against the
Company, are in full force and effect and, upon consummation of the Merger, shall continue in full
force and effect without penalty, acceleration, termination, repurchase right or other adverse
consequence. The Company and each of its Subsidiaries has in all material
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">respects performed all
material obligations required to be performed by it to date under each Significant Contract.
Neither the Company nor any of its Subsidiaries knows of, or has received notice of, the existence
of any event or condition which constitutes, or, after notice or lapse of time or both, will
constitute a default on the part of the Company or any of its Subsidiaries under any such
Significant Contract, except where such default has not had, and would not reasonably be expected
to have, either individually or in the aggregate, a Company Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12. <U>Disclosure Documents</U>. The proxy statement and all related SEC filings (the
&#147;<U>Proxy Materials</U>&#148;) relating to the Merger and the other transactions contemplated hereby,
to be filed by the Company with the SEC in connection with seeking the adoption and approval of
this Agreement by the Company stockholders will not, at the date first mailed to stockholders of
the Company or at the time of the Stockholders&#146; Meeting (other than with respect to any information
supplied by Parent or Merger Sub for inclusion therein) contain any untrue statement of material
fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading;
<U>provided</U>, <U>however</U>, that this representation and warranty shall not apply to any
information so provided by the Company that subsequently changes or becomes incomplete or incorrect
to the extent such changes or failure to be complete or correct are promptly disclosed to Parent,
and the Company subsequently prepares, files or disseminates updated information to the extent
required by Law. The Company will cause the Proxy Materials to comply as to form in all material
respects with the requirements of the Exchange Act applicable thereto. No representation is made
by the Company with respect to statements made in the Proxy Materials based on information supplied
by Parent or Merger Sub specifically for inclusion therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.13. <U>Employee Benefit Plans</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Section&nbsp;5.13</U> of the Company Disclosure Schedule sets forth a list of all material
&#147;employee benefit plans,&#148; as defined in Section&nbsp;3(3) of the Employee Retirement Income Security Act
of 1974, as amended (&#147;<U>ERISA</U>&#148;), and all other material plans, policies, agreements, programs
and arrangements that provide for compensation, retention, termination, severance, deferred
compensation, pension, retirement, employment, change in control, fringe or any other employee
benefit or that provide for performance awards and stock or stock-related awards, and that are
maintained by the Company or any Subsidiary of the Company, or to which the Company or any
Subsidiary of the Company is party thereto or
obligated to contribute thereunder for current or former employees or directors of the Company
or any Subsidiary of the Company (the &#147;<U>Benefit Plans</U>&#148;). True, correct and complete copies
of the following documents, with respect to each Benefit Plan, have been delivered or made
available to Parent (in each case, if any): (i)&nbsp;current, accurate and complete copies of all
documents embodying or relating to each Benefit Plan, including all amendments thereto, and trust
agreements with respect thereto; (ii)&nbsp;the two (2)&nbsp;most recent annual actuarial valuations, if any,
prepared for each Benefit Plan; (iii)&nbsp;the two (2)&nbsp;most recent annual reports (Series&nbsp;5500 and all
schedules thereto), if any, required under ERISA in connection with each Benefit Plan or related
trust; (iv)&nbsp;the most recent determination letter received from the Internal Revenue Service
(&#147;<U>IRS</U>&#148;), if any, for each Benefit Plan and related trust which is intended to satisfy the
requirements of Section 401(a) of the Code; (v)&nbsp;if the Benefit Plan is funded, the most recent
annual and periodic accounting of Benefit Plan assets; (vi)&nbsp;the most recent summary plan
description together with the most recent summary of material modifications, if any, required under
ERISA with respect to each Benefit Plan; and (vi)&nbsp;all
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">material communications to any employee or
participant or employees or participants relating to each Benefit Plan that will be required to be
described in a summary of material modifications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the Company nor any Subsidiary of the Company has adopted or announced any plan or
commitment (other than any plan or commitment that has already been completed) to establish any new
material Benefit Plan, or to modify or to terminate any Benefit Plan (except to the extent required
by law or to conform any such Benefit Plan to the requirements of any applicable law, in each case
in a manner that would not have the effect of materially increasing benefits thereunder, or as
required or contemplated by this Agreement), nor has any intention to do any of the foregoing been
communicated to any Company directors, consultants, independent contractors or employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;No Benefit Plan is subject to Title IV of ERISA, and no circumstances exist that could
result in liability to the Company, any Subsidiary of the Company or an ERISA Affiliate under Title
IV or Section&nbsp;302 of ERISA, except for such liability as would not, individually or in the
aggregate, be material. At no time during the last six years has the Company, any Subsidiary of
the Company or any of their respective ERISA Affiliates contributed to or been required to
contribute to, or incurred any withdrawal liability (within the meaning of Section&nbsp;4201 of ERISA)
to any Benefit Plan that is &#147;multi-employer plan&#148; within the meaning of Sections&nbsp;3(37) or
4001(a)(3) of ERISA. The term &#147;<U>ERISA Affiliate</U>&#148; means any Person that is considered one
employer with the Company under Section&nbsp;4001 of ERISA or Section&nbsp;414 of the Code. Neither the
Company nor any Subsidiary of the Company maintains, is or will be required to provide, medical or
other welfare benefits to employees, directors, former employees, former directors or retirees
after their termination of employment or service, other than pursuant to applicable Law or benefits
in the nature of severance pay with respect to one or more of the employment contracts set forth on
<U>Section&nbsp;5.13</U> of the Company Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Each Benefit Plan that is intended to qualify under Section&nbsp;401 of the Code, and each
trust maintained pursuant thereto, has received a favorable determination letter from the IRS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;All Benefit Plans were established and have been maintained and administered in all
material respects in accordance with their terms and in accordance with all applicable Laws. No
&#147;prohibited transaction,&#148; within the meaning of Section&nbsp;4975 of the Code or Section&nbsp;406 of ERISA,
has occurred with respect to any Benefit Plan that would reasonably be expected to result in any
material liability. No action or failure to act and no transaction or holding of any asset by, or
with respect to, any Benefit Plan has or, to the Knowledge of the Company or any Subsidiary,
reasonably would subject the Company, Parent, any Subsidiary of the Company or any ERISA Affiliate
or any fiduciary to any material tax, penalty or other liability, whether by way of indemnity or
otherwise. No event or transaction has occurred with respect to any Benefit Plan that would result
in the imposition of any material tax under Chapter&nbsp;43 of Subtitle D of the Code. There are no
pending or, to the Knowledge of the Company, threatened claims against the Benefit Plans, any
related trusts, any Benefit Plan sponsor or plan administrator, or any fiduciary of the Benefit
Plans with respect to the operation of such plans (other than routine benefit claims), except for
such claims as have not been individually or in the aggregate, and would not reasonably be expected
to be, material. Except as would not,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">individually or in the aggregate, reasonably be expected to
be material, all Benefit Plans subject to the laws of any jurisdiction outside of the United States
(i)&nbsp;if they are intended to qualify for special tax treatment meet all requirements for such
treatment and (ii)&nbsp;if they are intended to be funded and/or book-reserved are fully funded and/or
book reserved, as appropriate, based upon reasonable actuarial assumptions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;No Benefit Plan is under audit or investigation by the IRS, the Department of Labor, the
Pension Benefit Guaranty Corporation or the Department of Health and Human Services and to the
Knowledge of the Company or any Subsidiary of the Company, no such audit or investigation is
pending or threatened. To the Knowledge of the Company, all Benefit Plans are, and have been
maintained, to the extent applicable, in &#147;good faith compliance&#148; with Section&nbsp;409A of the Code
(within the meaning of the preambles to the proposed regulations thereunder). Each Benefit Plan
can be amended, terminated or otherwise discontinued in accordance with its terms (as in effect on
the date hereof) without material liability to the Company or any Subsidiary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Except for (i)&nbsp;any acceleration of vesting specifically provided for or contemplated by
this Agreement, (ii)&nbsp;any provision of a Benefit Plan disclosed in <U>Section&nbsp;5.13</U> of the
Company Disclosure Schedule, and (iii)&nbsp;the adoption of the severance plan described in <U>Section
7.8</U>, neither the execution and delivery of this Agreement nor the consummation of the
transactions contemplated hereby (either alone or in conjunction with another event, such as a
termination of employment) will (i)&nbsp;result in any payment becoming due to any current or former
director or current or former employee of the Company or any of its Subsidiaries under any Benefit
Plan or otherwise; (ii)&nbsp;increase any benefits otherwise payable under any Company Benefit Plan; or
(iii)&nbsp;result in any acceleration of the time of payment or vesting of any such benefits.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;There is no outstanding order against the Benefit Plans that is, and would reasonably be
expected to be, material.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;There is no commitment covering any employee that, individually or in the aggregate, would
be reasonably likely to give rise to the payment of any amount that would result in a material loss
of tax deductions pursuant to Section 162(m) of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;The Company is not obligated, pursuant to any Benefit Plan or otherwise, to grant any
options to purchase shares of Company stock to any Employees, consultants or directors of the
Company after the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;All contributions, reserves or premium payments required to be made or accrued as of the
date hereof to the Benefit Plans have been timely made or accrued in all material respects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;The Company and each Subsidiary of the Company (i)&nbsp;is in compliance in all material
respects with all applicable federal, state and local laws, rules and regulations (domestic and
foreign) respecting employment, employment practices, labor, terms and conditions of employment and
wages and hours, in each case, with respect to each of their current (including those on layoff,
disability or leave of absence, whether paid or unpaid),
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">former, or retired employees, officers,
consultants, independent contractors providing individual services, agents or directors of the
Company or any Subsidiary of the Company (collectively, &#147;<U>Employees</U>&#148;); and (ii)&nbsp;is not
liable for any material payment to any trust or other fund or to any governmental or administrative
authority, with respect to unemployment compensation benefits, social security or other benefits
for Employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;No work stoppage or labor strike against the Company or any Subsidiary of the Company by
Employees is pending or, to the Knowledge of the Company and its Subsidiaries, threatened. Neither
the Company nor any Subsidiary of the Company (i)&nbsp;is involved in or, to the Knowledge of the
Company and its Subsidiaries, threatened with any material labor dispute, grievance, or litigation
relating to labor matters involving any Employees, including, without limitation, violation of any
federal, state or local labor, safety or employment laws (domestic or foreign), charges of unfair
labor practices or discrimination complaints; (ii)&nbsp;has engaged in any unfair labor practices within
the meaning of the National Labor Relations Act; or (iii)&nbsp;is presently, nor has been in the past a
party to, or bound by, any collective bargaining agreement or union contract with respect to
Employees and no such agreement or contract is currently being negotiated by the Company. No
Employees are currently represented by any labor union for purposes of collective bargaining, and,
to the Knowledge of the Company and its Subsidiaries, no activities the purpose of which is to
achieve such representation of all or some of such Employees are ongoing or threatened, or have
resulted in any petition for a representation election filed with the National Labor Relations
Board in the past three months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;The Company and its Subsidiaries do not have any material liability, contingent or
otherwise, to, or with respect to, any benefit plan (other than the Benefit Plans listed on Section
5.13 of the Company Disclosure Schedule) that is now or previously has been sponsored, maintained,
contributed to, or required to be contributed to by, any ERISA Affiliate (other than one of the
Company&#146;s Subsidiaries).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.14. <U>Intellectual Property</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Section&nbsp;5.14</U> of the Company Disclosure Schedule sets forth a true and complete
list of all (i)&nbsp;patents, patent applications, trademark registrations and applications therefor,
domain name registrations and copyright registrations and applications therefor, in each case,
included in the Owned Intellectual Property as of the date hereof (&#147;<U>Owned Registered
Intellectual Property</U>&#148;), except Owned Registered Intellectual Property that is not currently
material to the Company&#146;s or its Subsidiaries&#146; business and (ii)&nbsp;material Contracts relating to the
acquisition, transfer, development, license, sublicense and disclosure of Intellectual Property
used or held for use by the Company or any of its Subsidiaries, excluding Contracts relating to
licensing generally available, commercial software, research re-agents, kits, detection systems,
instruments, equipment, assays and the like (&#147;<U>IP Agreements</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;To the Knowledge of the Company, all Owned Registered Intellectual Property is valid,
subsisting and enforceable. No Owned Intellectual Property is subject to any outstanding
settlement, order, ruling, judgment or decree adversely affecting the use thereof or rights thereto
by the Company or any of its Subsidiaries. The Company and its Subsidiaries are the exclusive
owner(s) or joint owner(s) of all Owned Intellectual Property free and clear of any encumbrances
(excluding licenses granted to third parties in the ordinary course of Company&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and its
Subsidiaries&#146; businesses). No Owned Registered Intellectual Property (except Owned Registered
Intellectual Property that is not currently material to the Company&#146;s or its Subsidiaries&#146;
business) has lapsed, expired or been abandoned or cancelled or nullified, or is currently subject
to any pending, or threatened, opposition, cancellation, nullification, interference, public
protest, domain name dispute, reexamination, reissue or other proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;To the Knowledge of the Company, the conduct of the business by the Company and its
Subsidiaries since January&nbsp;1, 2003 has not infringed and does not infringe, dilute, misappropriate
or otherwise violate the Intellectual Property rights of any third Person in any material respect.
Since January&nbsp;1, 2003, no claim, action, litigation or other proceeding has been asserted in
writing, or to the Knowledge of the Company, threatened or any basis for threatening (including,
without limitation, cease and desist letters or offers for license), against the Company or any
indemnitee of the Company concerning the ownership, validity, registerability, enforceability,
infringement, dilution, misappropriation, use or licensed right to use any Owned Intellectual
Property, Licensed-In Intellectual Property or other Intellectual Property rights of any third
Person. To the Knowledge of the Company, no third party is infringing, diluting, misappropriating
or violating the Owned Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Except as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect and except as a result of any agreements, contracts, licenses and
agreements that Parent or the Merger Sub is subject to prior to the consummation of the
transactions contemplated by this Agreement, the execution, delivery and performance by the Company
of the transactions contemplated by this Agreement will not (i)&nbsp;alter, impair, diminish or result
in the loss of any rights or interests of the Company or any of its Subsidiaries in any Owned
Intellectual Property or Licensed-In Intellectual Property, (ii)&nbsp;grant or require the Company or
any of its Subsidiaries to grant to any Person any rights with respect to any Owned Intellectual
Property or Licensed-In Intellectual Property, or (iii)&nbsp;subject the Company or any of its
Subsidiaries to any increase in or acceleration of royalties or other payments in respect of any
Licensed-In Intellectual Property. The Company and its Subsidiaries
have taken and are now taking reasonable measures under the circumstances to maintain the
confidentiality of any material trade secrets constituting Owned Intellectual Property.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;There are not ongoing interferences, oppositions, reissues, or reexaminations or other
inter-party proceedings which could reasonably be expected to result in a loss or limitation of a
patent right or claim involving any of the patents or patent applications listed on Section&nbsp;5.14 of
the Company Disclosure Schedule and owned by the Company or any of its Subsidiaries that would
reasonably be expected, either individually or in the aggregate, to have a Company Material Adverse
Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;All personnel, including current and former employees, agents, consultants, officers and
contractors who have contributed to or participated in the conception and development of any of the
material Intellectual Property owned by the Company or any of its Subsidiaries either (A)&nbsp;have been
party to a &#147;work-for-hire&#148; arrangement or agreement with the Company or its Subsidiaries, whether
in accordance with applicable federal and state law, domestic or foreign, or otherwise, that has
accorded the Company or its Subsidiaries ownership of all tangible and intangible property rights
thereby arising, or (B)&nbsp;have executed appropriate instruments of assignment in favor of the Company
or its Subsidiaries as assignees that have
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">conveyed to the Company or its Subsidiaries all of such
Person&#146;s rights in or to such Intellectual Property.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As used herein,
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) &#147;<U>Intellectual Property</U>&#148; means, collectively, all United States and
non-United States (i)&nbsp;trademarks, service marks, brand names, certification marks,
collective marks, d/b/a&#146;s, Internet domain names, logos, symbols, trade dress, assumed
names, fictitious names, trade names and other indicia of origin, all applications and
registrations for the foregoing, and all goodwill associated therewith and symbolized
thereby, including all renewals of same; (ii)&nbsp;inventions and discoveries, whether patentable
or not, and all patents, registrations (including statutory invention registrations),
invention disclosures, including all renewals, extensions, re-examinations, reissues and
supplemental protection certificates thereof and all applications for the foregoing,
including all provisionals, divisions, continuations, continuations-in-part and renewal
applications; (iii)&nbsp;trade secrets and confidential or proprietary information and know-how,
including, without limitation, compositions, processes, methods, data, schematics, business
methods, formulae, drawings, prototypes, models, designs, customer lists and supplier lists;
(iv)&nbsp;published and unpublished works of authorship, whether copyrightable or not, copyrights
therein and thereto, and registrations and applications therefor, and all renewals,
extensions, restorations and reversions thereof, and (v)&nbsp;all other intellectual and
industrial property not enumerated or described above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) &#147;<U>Licensed-In </U>Intellectual<U> Property</U>&#148; means the Intellectual Property
which is licensed to or otherwise made available for use by the Company or any of its
Subsidiaries pursuant to any Contracts for Intellectual Property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) &#147;<U>Owned Intellectual Property</U>&#148; means the Intellectual Property owned by the
Company or any of its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.15. <U>Taxes</U>. (i)&nbsp;The Company and each of its Subsidiaries have prepared in good faith
and duly and timely filed (taking into account any valid extension of time within which to file)
all material Tax Returns required to be filed by any of them and all such filed Tax Returns are
complete and accurate in all material respects; (ii)&nbsp;the Company and each of its Subsidiaries have
timely paid or caused to be paid all Taxes that are required to be paid by any of them (whether or
not shown on any Tax Return) and the Company and each of its Subsidiaries have timely withheld and
paid all Taxes required to have been withheld and paid by any of them in connection with any
amounts paid or owing to any employee, independent contractor, stockholder, creditor or other third
party; (iii)&nbsp;all material deficiencies asserted in writing or assessments made as a result of any
examinations or other audits by federal, state, local or foreign taxing authorities have been paid
in full, settled or adequately provided for in the financial statements contained in the Company
Reports filed on or prior to the date of this Agreement; (iv)&nbsp;no federal or material state, local
or foreign tax audit or administrative or judicial proceeding is pending or being conducted with
respect to the Company or any of its Subsidiaries, and neither the Company nor any of its
Subsidiaries has received from any federal, state, local or foreign taxing authority any written
notice indicating an intent to open an audit or other review; (v)&nbsp;there are no outstanding
agreements or waivers extending the statutory period
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of limitations applicable to any material Tax
Return of the Company or any of its Subsidiaries; (vi)&nbsp;neither the Company nor any of its
Subsidiaries is bound by any Tax sharing agreement with third parties; (vii)&nbsp;neither the Company
nor any of its Subsidiaries is a party to any &#147;listed transaction&#148; as defined in Treasury
Regulation&nbsp;Section&nbsp;1.6011-4(b)(2); and (viii)&nbsp;neither the Company nor any of its Subsidiaries has
any material liability for the Taxes of any Person (other than the Company and its Subsidiaries)
under Treasury Regulation&nbsp;Section&nbsp;1.1502-6 (or any comparable provision of state, local or foreign
Law), as a transferee or successor, by contract or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.16. <U>No Payments Not Deductible Pursuant to Section&nbsp;280G</U>. Neither the execution and
delivery of this Agreement nor the consummation of the transactions contemplated hereby will
(either alone or in conjunction with any other event): (i)&nbsp;result in, cause the accelerated
vesting, funding or delivery of, or increase the amount or value of, any payment or benefit to any
employee, officer or director of the Company or any of its subsidiaries or (ii)&nbsp;result in the
triggering or imposition of any restrictions or limitations on the right of the Company or Parent
to amend or terminate any Benefit Plan and receive the full amount of any excess assets remaining
or resulting from such amendment or termination, subject to applicable taxes. Without limiting the
generality of the foregoing, no amount paid or payable (whether in cash, in property, or in the
form of benefits) by the Company or any of its Subsidiaries in connection with the transactions
contemplated hereby (either solely as a result thereof or as a result of such transactions in
conjunction with any other event) will be an &#147;excess parachute payment&#148; within the meaning of
Section&nbsp;280G of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.17. <U>Real Property; Leasehold</U>. Neither the Company nor any of its Subsidiaries own
any real property or any interest in any real property, except for the leaseholds created under the
real property leases identified in Section&nbsp;5.17 of the Company Disclosure Schedule. The Company
and each of its Subsidiaries have a valid leasehold in all real property and other material
properties and assets leased by the Company or its Subsidiaries, in each case free of all pledges,
claims, liens, encumbrances and security interests of any kind or nature
whatsoever, except where the failure to have such title does not have, and would not
reasonably be expected to have, either individually or in the aggregate, a Company Material Adverse
Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.18. <U>Environmental Matters</U>. (a)&nbsp;Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect: (i)&nbsp;no real property
(including soils, groundwater, surface water, buildings or other structures thereon or thereunder)
owned, operated, used or occupied by the Company or any of its Subsidiaries has been contaminated
as a result of release, spill, discharge or disposal of any Hazardous Substance during or, to the
Knowledge of the Company, prior to, the ownership or operation or use by the Company or any of its
Subsidiaries, in each case that would be reasonably likely to require investigation and/or
remediation pursuant to Environmental Law; (ii)&nbsp;no real property formerly owned or operated or used
by the Company or any of its Subsidiaries was contaminated as a result of release, spill, discharge
or disposal of any Hazardous Substance during or, to the Knowledge of the Company, prior to, the
ownership or operation or use by the Company or any of its Subsidiaries, in each case that would be
reasonably likely to require investigation and/or remediation pursuant to Environmental Law; (iii)
neither the Company nor any of its Subsidiaries has received any written notice, demand, letter,
claim or request for information from any Governmental Entity or other third party indicating that
the Company or any of its
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Subsidiaries may be in material violation of or subject to material
liability under any Environmental Law or arising from Hazardous Substances; (iv)&nbsp;neither the
Company nor any of its
Subsidiaries is subject to any material order, decree, injunction or other
arrangement with any Governmental Entity or is a party to any indemnity or any other agreement with
any third party under any Environmental Law or otherwise relating to any Hazardous Substances; and
(v)&nbsp;the Company and its Subsidiaries have obtained in a timely manner, maintained in effect, and
are in material compliance with, all Permits required by applicable Environmental Law in connection
with the business of the Company and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company has delivered, or made available to Parent true and complete copies and
results of any reports, studies, analyses, tests or monitoring possessed or initiated by the
Company pertaining to Environmental Law.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As used herein:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The term &#147;<U>Environmental Law</U>&#148; means any Law (including without limitation
principles of common law, directives, statutes, their implementing laws and regulations,
related judicial and administrative orders and binding legal interpretations thereof)
applicable to the Company or any of its Subsidiaries relating to pollution or protection of
the environment, natural resources, human health or safety, including without limitation
Laws relating to the generation, handling, use, presence, transportation, recycling,
take-back, disposal, release or threatened release of any Hazardous Substance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The term &#147;<U>Hazardous Substance</U>&#148; means any substances, mixtures, chemicals,
products, materials or wastes that, pursuant to Environmental Law, are listed, classified,
characterized, defined or regulated as hazardous, biohazardous, dangerous, infectious,
toxic, a pollutant or a contaminant, including without limitation petroleum, petroleum
products or by-products, friable
asbestos, biological agents, genetically engineered or modified materials, blood-borne
pathogens, bacterial or fungal materials, medical waste, unused or &#147;off-spec&#148; products, any
material or equipment containing radon or other radioactive materials or polychlorinated
biphenyls.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.19. <U>Insurance</U>. The Company has made available to Parent accurate and complete
copies of all material insurance policies and all material self insurance programs and arrangements
relating to the business, assets, liabilities and operations of the Company and its Subsidiaries.
To the Knowledge of the Company, each of such insurance policies is in full force and effect.
Since January&nbsp;1, 2005, neither the Company nor any of its Subsidiaries has received any notice or
other communication regarding any actual or possible: (a)&nbsp;cancellation or invalidation of any
insurance policy; (b)&nbsp;refusal or denial of any material coverage, reservation of rights or
rejection of any material claim under any insurance policy; or (c)&nbsp;material adjustment in the
amount of the premiums payable with respect to any insurance policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.20. <U>Takeover Statutes; Charter Provisions</U>. The Company Board has approved the
Merger, this Agreement and the Voting Agreements, and such approval is sufficient to render
inapplicable to the Merger, this Agreement and the Voting Agreements the limitations on business
combinations contained in any restrictive provision of any &#147;fair price,&#148; &#147;moratorium,&#148;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;control share acquisition,&#148; &#147;interested stockholder&#148; or other similar anti-takeover statute or regulation
(including, without limitation, Section&nbsp;203 of the DGCL to the extent applicable) (&#147;<U>Takeover
Statute</U>&#148;) or restrictive provision of any applicable anti-takeover provision in the Company&#146;s
Amended and Restated Certificate of Incorporation or Bylaws. No other state takeover statute or
similar statute or regulation or other comparable takeover provision of the Company&#146;s Amended and
Restated Certificate of Incorporation or Amended and Restated Bylaws applies to the Merger, this
Agreement, the Voting Agreements or any of the transactions contemplated hereby or thereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.21. <U>Brokers</U>. No broker, finder, investment banker or other third party other than
Goldman, Sachs &#038; Co., is entitled to any brokerage, finders&#146; or other fee or commission in
connection with the transactions contemplated hereby based upon arrangements made by or on behalf
of the Company or any of its Subsidiaries. The Company has made available to Parent a correct and
complete copy of the Company&#146;s engagement letter with Goldman, Sachs &#038; Co. applicable with respect
to the Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.22. <U>Rights Agreement</U>. The Company Board has taken all requisite action such that
none of Parent, Merger Sub or any of their affiliates shall become an &#147;Acquiring Person,&#148; and no
&#147;Shares Acquisition Date&#148; or &#147;Distribution Date&#148; (as such terms are defined in the Rights
Agreement) will occur, solely by reason of the approval, execution or delivery of this Agreement or
the Voting Agreements or the consummation of the transactions contemplated hereby or thereby and
such that the Expiration Date (as such term is defined in the Rights Agreement) will occur
immediately prior to the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.23. <U>Third Party Supply</U>. As of the date hereof, there are no outstanding forecasts
or orders with respect to materials supplied or manufactured, or to be supplied or manufactured, by
the Company or any of its Subsidiaries to any third parties. No further orders
to supply such materials to third parties are expected to be received by the Company or any of
its Subsidiaries.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Representations and Warranties<BR>
of Parent and Merger Sub</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent and Merger Sub hereby represent and warrant to the Company as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1. <U>Organization, Good Standing and Qualification</U>. Each of Parent and Merger Sub is
a corporation or other legal entity duly organized, validly existing and in good standing under the
Laws of the jurisdiction of its incorporation or organization and has all requisite corporate or
other power and authority to own, lease and operate its properties and assets and to carry on its
businesses as now being conducted and is qualified to do business and is in good standing as a
foreign corporation in each jurisdiction where the ownership, leasing or operation of its
properties or assets or conduct of its business requires such qualification, except where the
failure to be so qualified or in good standing or to have such power or authority, would not,
individually or in the aggregate, reasonably be expected to prevent or materially delay or
materially impair the ability of Parent or Merger Sub to consummate the Merger and the other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">transactions contemplated by this Agreement. Parent has heretofore delivered or made available to
the Company accurate and complete copies of the Certificate of Incorporation and Bylaws (or similar
governing documents), as currently in effect, of Parent and Merger Sub.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2. <U>Authority Relative to this Agreement</U>. Each of Parent and Merger Sub has all
necessary corporate power and authority, and has taken all action necessary, to execute, deliver
and perform under this Agreement and to consummate the transactions contemplated hereby in
accordance with the terms hereof, except for the consent of Parent as sole stockholder of Merger
Sub, which will be effected by written consent immediately after the execution of this Agreement.
This Agreement has been duly and validly executed and delivered by each of Parent and Merger Sub,
and assuming due authorization, execution and delivery hereof by the Company, constitutes a valid,
legal and binding agreement of each of Parent and Merger Sub, enforceable against each of Parent
and Merger Sub in accordance with its terms except for (i)&nbsp;the effect of any applicable bankruptcy,
insolvency, reorganization, moratorium and similar laws relating to or affecting the rights of
creditors generally and (ii)&nbsp;the effect of equitable principles of general application.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3. <U>Consents and Approvals; No Violations</U>. No filing with or notice to, and no
permit, authorization, registration, consent or approval of, any Governmental Entity is required on
the part of Parent or Merger Sub or any of their Subsidiaries for the execution, delivery and
performance by Parent and Merger Sub of this Agreement or the consummation by Parent or Merger Sub
of the transactions contemplated hereby, other than (i)&nbsp;as set forth in <U>Schedule&nbsp;6.3</U>; (ii)
pursuant to the applicable requirements of the Securities Act and the Exchange Act; (iii)&nbsp;the
filing of the Certificate of Merger pursuant to the DGCL; (iv)&nbsp;compliance with the HSR Act; (v)
such filings or notices as may be required under any environmental, health or safety Law (including
any rules and regulations of the FDA) in connection with the Merger; or
(vi)&nbsp;compliance with any applicable requirements of laws, rules and regulations in other
foreign jurisdictions governing antitrust or merger control matters.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4. <U>Merger Sub</U>. All of the issued and outstanding capital stock of Merger Sub is,
and at the Effective Time will be, owned by Parent or a direct or indirect wholly-owned Subsidiary
of Parent. Merger Sub was formed solely for the purpose of effecting the Merger. Merger Sub has
not conducted any business prior to the date hereof and has no, and prior to the Effective Time
will have no, assets, liabilities or obligations of any nature other than those incident to its
formation and pursuant to this Agreement and the Merger and the other transactions contemplated by
this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5. <U>Disclosure Documents</U>. None of the information supplied or to be supplied by
Parent or Merger Sub specifically for inclusion in the Proxy Materials, at the date it is first
mailed to stockholders of the Company or at the time of the Stockholders&#146; Meeting contain any
untrue statement of material fact or omit to state any material fact required to be stated therein
or necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading; <U>provided</U>, <U>however</U>, that this representation and
warranty shall not apply to any information so provided by Parent or Merger Sub that subsequently
changes or becomes incomplete or incorrect to the extent such changes or failure to be complete or
correct are promptly disclosed to the Company, and Parent and Merger Sub

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reasonably cooperate with
the Company in preparing, filing or disseminating updated information to the extent required by
Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6. <U>Availability of Funds</U>. Parent has on the date hereof sufficient funds and shall
have available at the Effective Time sufficient funds to enable it to consummate the Merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7. <U>Brokers</U>. No broker, finder or investment banker is entitled to any brokerage,
finders&#146; or other fee or commission in connection with the transactions contemplated hereby based
upon arrangements made by or on behalf of Parent or Merger Sub that would be binding on the Company
if the Agreement is terminated prior to Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8. <U>Access</U>. Parent, on behalf of itself and Merger Sub, has conducted its own
independent investigation of the Company and has, to its Knowledge, been furnished by the Company,
or its agents or representatives, with all information, documents and other materials relating to
the Company, and its business, management, operations and finances, that Parent and Merger Sub
believe is necessary to enter into this Agreement. In making its decision to execute and deliver
this Agreement and to consummate the transactions contemplated hereby, Parent and Merger Sub have
relied solely upon the representations and warranties of the Company set forth in Article&nbsp;V hereof
and have not relied upon any other information provided by, for or on behalf of the Company, or its
agents or representatives, to Parent or Merger Sub in connection with the transactions contemplated
by this Agreement.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Covenants of the Parties</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1. <U>Operations of the Company&#146;s Business</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as set forth in the corresponding section of the Company Disclosure Schedule, as
otherwise contemplated hereby or as may be agreed in advance by Parent (and, if asked, Parent will
not unreasonably delay its response), subject to applicable Law, the Company covenants and agrees
as to itself and its Subsidiaries that, from the date of this Agreement until the Effective Time,
the business of it and its Subsidiaries shall be conducted only in the ordinary course and, to the
extent consistent therewith, it and its Subsidiaries shall use their respective commercially
reasonable efforts to preserve its business organization intact and maintain its existing relations
and goodwill with Governmental Entities, customers, suppliers, distributors, creditors, lessors,
employees and business associates. Without limiting the generality of the foregoing and in
furtherance thereof, from the date of this Agreement until the Effective Time, except as set forth
in the corresponding section of the Company Disclosure Schedule, as otherwise contemplated hereby
or as may be agreed in advance by Parent (and, if asked, Parent will not unreasonably delay its
response), subject to applicable Law and the regulations or requirements of any stock exchange or
regulatory organization applicable to the Company, the Company will not and will not permit its
Subsidiaries to:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) adopt or propose any change in its certificate of incorporation or Bylaws (or
similar governing documents);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) merge or consolidate the Company or any of its Subsidiaries with any other Person,
except for any such transactions among wholly-owned Subsidiaries of the Company that are not
obligors or guarantors of third party indebtedness;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) acquire assets outside of the ordinary course of business from any other Person
with a value or purchase price in the aggregate in excess of $100,000 other than
acquisitions pursuant to Contracts to the extent in effect immediately prior to the
execution of this Agreement and set forth in <U>Section&nbsp;7.1(a)(iii)</U> of the Company
Disclosure Schedule or as otherwise set forth in <U>Section&nbsp;7.1(a)(iii)</U> of the Company
Disclosure Schedule;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) other than pursuant to Contracts set forth in <U>Section&nbsp;7.1(a)(iv)</U> of the
Company Disclosure Schedule, and other than the issuance of shares of Common Stock upon the
exercise of Company Stock Options outstanding on the date hereof, granted pursuant to the
terms of this Agreement or pursuant to the ESPP, in each case, in accordance with their
terms, as in effect on the date hereof, issue, sell, pledge, dispose of, grant, transfer,
lease, license, guarantee, encumber, or authorize the issuance, sale, pledge, disposition,
grant, transfer, lease, license, guarantee or encumbrance of, any shares of capital stock of
the Company or any of its Subsidiaries or securities convertible or exchangeable or
exercisable for any shares of such capital stock, or any options, warrants or other rights
of any kind to acquire any shares of such capital stock or such convertible or exchangeable
securities (other than the grant of Company Stock Options to
new hires in the ordinary course of business consistent with past practice in an amount
not to exceed 50,000 per 30-day period and 200,000 in the aggregate);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) create or incur any Lien on assets of the Company or any of its Subsidiaries that
is material, individually or in the aggregate, to the Company and its Subsidiaries taken as
a whole;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) other than pursuant to Contracts to the extent in effect as of immediately prior
to the execution of this Agreement and set forth in <U>Section&nbsp;7.1(a)(vi)</U> of the
Company Disclosure Schedule, make any loan, advance or capital contribution to or investment
in any Person (other than a wholly-owned Subsidiary of the Company) in excess of $100,000 in
the aggregate;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) declare, set aside, make or pay any dividend or other distribution, payable in
cash, stock, property or otherwise, with respect to any of its capital stock (except for
dividends or other distributions by any direct or indirect wholly-owned Subsidiary of the
Company to the Company or to any other direct or indirect wholly-owned Subsidiary of the
Company and periodic dividends and other periodic distributions by non-wholly-owned
Subsidiaries in the ordinary course consistent with past practices) or enter into any
agreement with respect to the voting of its capital stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) reclassify, combine, split, subdivide or redeem, purchase or otherwise acquire,
directly or indirectly, any of its capital stock or securities convertible or exchangeable
into or exercisable for any shares of its capital stock except the acceptance of shares of
Common Stock as payment of the exercise price of stock options
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">or for withholding taxes
incurred in connection with the exercise of Company Stock Options or the vesting of
restricted stock or other Company stock-based awards, in each case in accordance with past
practice and the terms of the applicable award;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) incur any indebtedness for borrowed money or guarantee such indebtedness of
another Person, or issue or sell any securities or warrants or other rights to acquire any
security of the Company or any of its Subsidiaries, except for indebtedness for borrowed
money incurred in the ordinary course of business not to exceed $100,000 in the aggregate;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) except as set forth in <U>Section&nbsp;7.1(a)(x)</U> of the Company Disclosure Schedule
or as provided for in the Company&#146;s 2006 capital expenditure budget (attached to <U>Section
7.1(a)(x)</U> of the Company Disclosure Schedule), make or authorize any capital expenditure
in excess of $200,000;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) make any changes with respect to financial accounting policies or procedures,
except as required by changes in GAAP or by Law;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) commence any litigation or settle any litigation or other proceeding or other
investigation by or against the Company or any Subsidiary of the Company or relating to any
of their businesses, properties or assets, other than settlements (A)&nbsp;entered into in the
ordinary course of business consistent with past practice, (B)&nbsp;requiring of the Company and
its Subsidiaries only the payment of monetary damages not exceeding
$75,000, (C)&nbsp;not involving the admission of any wrongdoing by, the Company or any of
its Subsidiaries and (D)&nbsp;which would not be reasonably likely to have any adverse impact on
the operations of the Company or any of its Subsidiaries or on any current or future
litigation or other proceedings of the Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) sell, lease, license or otherwise dispose of any assets of the Company or its
Subsidiaries except for ordinary course sales of products or services provided in the
ordinary course of business or obsolete assets, and except for sales, leases, licenses or
other dispositions of assets with a fair market value not in excess of $50,000 in the
aggregate, other than pursuant to Contracts in effect prior to the execution of this
Agreement and set forth in <U>Section&nbsp;7.1(a)(xiii)</U> of the Company Disclosure Schedule
or as otherwise set forth in <U>Section&nbsp;7.1(a)(xiii)</U> of the Company Disclosure
Schedule;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) except as required pursuant to existing written, binding agreements or Benefit
Plans in effect prior to the execution of this Agreement set forth in <U>Section
7.1(a)(xiv)</U> of the Company Disclosure Schedule, or as otherwise required by Law or in
the ordinary course of business consistent with past practice with respect to new hires,
enter into, or commit to enter into any new employment or compensatory agreements
(including, but not limited to, the renewal of any consulting agreement) with any employee,
consultant or director of the Company or any of its Subsidiaries (including entering into
any bonus, severance, change of control, termination, reduction-in-force or consulting
agreement or other employee benefits arrangement or agreement pursuant to which such Person
has the right to any form of compensation from the Company or any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">of its Subsidiaries), or,
except for annual merit increases in the ordinary course of business consistent with past
practice for employees of the Company or its Subsidiaries other than officers, senior
managers or directors, increase the compensation and employee benefits of any employee,
consultant or director of the Company or any of its Subsidiaries, or adopt or amend any
Benefit Plan in any respect that would increase the cost of such Benefit Plan to the
Company, or accelerate vesting or payment under, any Benefit Plan;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) engage in the conduct of any new line of business, other than as expressly
permitted by <U>Section&nbsp;7.1(a)(xv)</U> of the Company Disclosure Schedule;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) make or change any Tax election, file any amended Tax Return (except as required
by applicable Law), enter into any closing agreement with respect to Taxes, settle any Tax
claim or assessment, surrender any right to claim a refund of Taxes, or consent to any
extension or waiver of the limitation period for the assessment of any Tax;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvii) enter into any material agreement with respect to any of its owned or
Licensed-in Intellectual Property or with respect to the intellectual property of any third
party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xviii) (A)&nbsp;enter into, modify or amend in a manner adverse to the Company or any of
its Subsidiaries, or terminate, any Significant Contract (or Contract
that would be a Significant Contract if such Contract had been entered into prior to
the date hereof) or any material manufacturing or supply agreement for any of the Company&#146;s
products or compounds or (B)&nbsp;waive, release or assign any material rights or claims
thereunder;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xix) create any new Subsidiaries; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xx) agree, resolve or commit to do any of the foregoing; <U>provided</U>,
<U>however</U>, that the foregoing covenants shall not prevent the Company and its
Subsidiaries from undertaking transactions between or among themselves.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2. <U>Acquisition Proposals</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company agrees that neither it nor any of its Subsidiaries nor any of the officers and
directors of it or its Subsidiaries shall, and that it shall not permit its and its Subsidiaries&#146;
employees, agents and representatives (including any investment banker, attorney, consultant or
accountant (&#147;<U>Representatives</U>&#148;) retained by it or any of its Subsidiaries) on its behalf to,
initiate, solicit or knowingly encourage any inquiries or the making of any proposal or offer from
any Person or group of Persons other than Parent or its affiliates, with respect to: (i)&nbsp;a merger,
reorganization, share exchange, consolidation, business combination, plan of liquidation or similar
transaction involving the Company; (ii)&nbsp;any purchase of 15% or more of any class of voting
securities of the Company or its Subsidiaries; or (iii)&nbsp;any purchase or sale of 15% or more of the
equity interest in the Company or the consolidated assets (on a book value basis) of the Company
and its Subsidiaries, taken as a whole (any such proposal or offer being hereinafter referred to as
an &#147;<U>Acquisition Proposal</U>&#148;). The Company further agrees that neither it nor any of

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">its Subsidiaries nor any of the officers and directors of it or its Subsidiaries shall, and that it
shall not permit its and its Subsidiaries&#146; Representatives to, (i)&nbsp;engage in any discussions or
negotiations with, or provide any confidential or non-public information or data to, any Person
relating to an Acquisition Proposal; (ii)&nbsp;knowingly encourage any effort or attempt to make or
implement an Acquisition Proposal; (iii)&nbsp;approve, recommend, agree to or accept, or propose to
approve, recommend, agree to or accept any Acquisition Proposal; (iv)&nbsp;approve, recommend, agree to
or accept, or execute or enter into, any letter of intent, agreement in principle, merger
agreement, acquisition agreement, option agreement or other similar agreement related to any
Acquisition Proposal; (v)&nbsp;withdraw, modify, qualify or change the Recommendation or (vi)&nbsp;resolve,
propose or agree to do any of the foregoing. The Company agrees that it, and its Subsidiaries will
immediately cease and cause to be terminated, and it will not permit its Representatives to
continue, any existing activities, discussions or negotiations with any Persons with respect to any
Acquisition Proposal (except with respect to the transactions contemplated by this Agreement).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Nothing contained in this Agreement shall prevent the Company or the Company Board from
(x)&nbsp;complying with its disclosure obligations under Sections&nbsp;14d-9 and 14e-2 of the Exchange Act
with regard to an Acquisition Proposal so long as any action taken or statement made to so comply
does not include a withdrawal, modification, qualification or change of the Recommendation in a
manner adverse to Parent that is made in contravention of Section&nbsp;7.3(b) (provided, however, that
any &#147;stop, look and listen&#148; or similar communication of the type contemplated by Rule&nbsp;14d-9(f)
under the Exchange Act shall not be deemed to be a
withdrawal, modification, qualification or change of the Recommendation in a manner adverse to
Parent) and (y)&nbsp;at any time prior to, but not after, the conditions set forth in Section&nbsp;8.1(a) has
been satisfied, and as long as there has not been a material or intentional failure to comply with
any of the obligations under this Section&nbsp;7.2 with respect to the applicable Acquisition Proposal
(A)&nbsp;providing information in response to a request therefor by a Person who has made an unsolicited
bona fide written Acquisition Proposal if the Company receives from the Person so requesting such
information an executed confidentiality agreement on terms no less restrictive on such Person than
the terms contained in the Confidentiality Agreement, and concurrently discloses the same
non-public information to Parent if such non-public information has not been previously disclosed
to Parent; (B)&nbsp;engaging in any negotiations or discussions with any Person who has made an
unsolicited bona fide written Acquisition Proposal if the Company receives from such Person an
executed confidentiality agreement as described in (A)&nbsp;above; or (C)&nbsp;withdrawing, modifying,
qualifying or changing the Recommendation so as to recommend such an unsolicited bona fide written
Acquisition Proposal to the stockholders of the Company, if and only to the extent that (I)&nbsp;in each
case referred to in clause (A), (B)&nbsp;or (C)&nbsp;above, the Company Board determines in good faith, after
consultation with its outside legal counsel, that such action is required to comply with the
Company directors&#146; fiduciary duties to stockholders of the Company under applicable Law, (II)&nbsp;in
each case referred to in clause (A), (B)&nbsp;or (C)&nbsp;above, the Company Board determines in good faith
after consultation with its outside legal counsel and financial advisors that such Acquisition
Proposal constitutes, or is reasonably likely to lead to, an Acquisition Proposal (which, for all
such purposes, shall substitute 50% for 15% in the definition thereof) that, if accepted, is
reasonably likely to be consummated, and if consummated, would result in a more favorable
transaction (taking into account legal, financial, regulatory and other aspects of such Acquisition
Proposal and the Merger and other transactions contemplated by this Agreement deemed relevant by
the Company Board, the identity of the third party making such

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Acquisition Proposal, the terms and
conditions of the Acquisition Proposal and the anticipated timing and prospects for completion of
such Acquisition Proposal) to the Company&#146;s stockholders than the transaction contemplated by this
Agreement (taking into account all of the terms of any proposal by Parent to amend or modify the
terms of the Merger and other transactions contemplated by this Agreement) (any such more favorable
Acquisition Proposal is referred to in this Agreement as a &#147;<U>Superior Proposal</U>&#148;), and (III)
in the case of clause (C)&nbsp;above, (i)&nbsp;Parent shall have been provided by the Company prompt written
notice of (x)&nbsp;the Company Board&#146;s intention to take the action referred to in clause (C)&nbsp;and (y)
the material terms and conditions of the Acquisition Proposal, including the identity of the party
making such Acquisition Proposal, and, if available, a copy of the relevant proposed transaction
agreements with such party and other material documents, (ii)&nbsp;the Company shall have given Parent
four business days after delivery of such notice to propose revisions to the terms of this
Agreement (or make another proposal) and shall have negotiated in good faith with Parent with
respect to such proposed revisions or other proposal, if any and (iii)&nbsp;the Company Board shall have
determined in good faith, after considering the results of such negotiations and giving effect to
the proposals made by Parent, if any, and after consultation with its outside legal counsel, that
such withdrawal, modification, qualification or change of the Recommendation is required to comply
with its fiduciary obligations to the stockholders of the Company under applicable Law; provided,
further that in the event the Company Board does not make the determination referred to in clause
(iii)&nbsp;of this paragraph but thereafter determines to withdraw, modify, qualify or change the
Recommendation pursuant to this Section&nbsp;7.2, the procedures referred to in clauses
(i), (ii)&nbsp;and (iii)&nbsp;shall apply anew and shall also apply to any subsequent withdrawal,
modification, qualification or change.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Company agrees that it will notify Parent promptly (and in any event within 24 hours
of the Company gaining Knowledge thereof) if any Acquisition Proposal, or any inquiry or indication
that would reasonably be expected to lead to any Acquisition Proposal, by any Person is received
by, any non-public information relating to the Company or any of its Subsidiaries is requested by
such a Person from, or any inquiry, discussions or negotiations regarding any Acquisition Proposal
are sought to be initiated by such a Person with, the Company, its Subsidiaries or any of its
Representatives. Such notice shall include the identity of the person making such Acquisition
Proposal, indication, inquiry or request and a copy of such Acquisition Proposal, indication,
inquiry or request (or, where no such copy is available, a description of such Acquisition
Proposal, indication, inquiry or request), including any modifications thereto. The Company shall
keep Parent reasonably informed on a current basis (and in any event within 24 hours of the
occurrence of any material changes, developments, discussions or negotiations) of the status of any
such Acquisition Proposal, indication, inquiry or request and of any material changes in the status
and terms of any such Acquisition Proposal, indication, inquiry or request (including the material
terms and conditions thereof). Without limiting the foregoing, the Company shall promptly (and in
any event within 24 hours) notify Parent orally and in writing if it determines to initiate actions
concerning an Acquisition Proposal as permitted by Section&nbsp;7.2(b) (y) (A)&nbsp;and (B). The Company
shall not, and shall cause it Subsidiaries not to, enter into any confidentiality agreement with
any Person subsequent to the date of this Agreement which prohibits the Company from providing such
information to Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3. <U>Stockholder Meeting; Proxy Material</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company shall duly call and shall use its commercially reasonable efforts to hold a
meeting of its stockholders (the &#147;<U>Stockholders&#146; Meeting</U>&#148;) for the purpose of obtaining the
approval of this Agreement and the Merger by the Company stockholders required to satisfy the
conditions set forth in Section&nbsp;8.1(a) as promptly as practicable following the date of this
Agreement. In connection with the Stockholders&#146; Meeting, the Company will (i)&nbsp;as promptly as
practicable following the date of this Agreement, prepare and file with the SEC the Proxy Materials
to the Merger and the other transactions contemplated hereby; (ii)&nbsp;respond as promptly as
reasonably practicable to any comments received from the SEC with respect to such filings and will
provide copies of such comments to Parent and Merger Sub promptly upon receipt; (iii)&nbsp;as promptly
as reasonably practicable, prepare and file (after Parent and Merger Sub have had a reasonable
opportunity to review and comment on) any amendments or supplements necessary to be filed in
response to any SEC comments or as required by Law; (iv)&nbsp;use its commercially reasonable efforts to
have cleared by the SEC, and will thereafter mail to its stockholders as promptly as reasonably
practicable, the Proxy Materials and all other customary proxy or other materials for meetings such
as the Stockholders&#146; Meeting; (v)&nbsp;to the extent required by applicable Law, as promptly as
reasonably practicable prepare, file and distribute to the Company stockholders any supplement or
amendment to the Proxy Materials if any event shall occur which requires such action at any time
prior to the Stockholders&#146; Meeting; and (vi)&nbsp;otherwise comply with all requirements of Law
applicable to the Stockholders&#146; Meeting and the Merger. The Company will provide Parent and Merger
Sub an opportunity to review and comment upon the Proxy Materials, or any
amendments or supplements thereto, or any SEC comments received with respect thereto, prior to
filing the same with the SEC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The written consent of Parent will be required to adjourn or postpone the Stockholders&#146;
Meeting; provided, that, in the event that there is present at such meeting, in person or by proxy,
sufficient favorable voting power to secure the Company Requisite Vote, the Company will not
adjourn or postpone the Stockholders&#146; Meeting unless the Company is advised by counsel that failure
to do so would result in a breach of the U.S. federal securities laws. Unless the Company Board
has changed its Recommendation pursuant to its fiduciary duties under applicable Law and in
compliance with Section&nbsp;7.2(b), the Recommendation of the Company Board shall be included in the
Proxy Materials, and the Company Board shall take all reasonable action to secure the adoption of
this Agreement by the holders of shares of Common Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4. <U>Commercially Reasonable Efforts; Cooperation</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Upon the terms and subject to the conditions of this Agreement, each of Parent, Merger Sub
and the Company agrees to use its commercially reasonable efforts to take, or cause to be taken,
all actions, and to do, or cause to be done, all things necessary, proper or advisable under any
applicable Laws to consummate and make effective the transactions contemplated hereby as promptly
as practicable including, but not limited to, (i)&nbsp;the preparation and filing of all forms,
registrations and notices required to be filed to consummate the transactions contemplated hereby
(including making or causing to be made the filings required under the HSR Act as promptly as
practicable and in any event within fifteen (15)&nbsp;business days after the date of this Agreement);
(ii)&nbsp;cooperating with the other in connection with the preparation and filing of any such forms,
registrations and notices (including, with respect to the party hereto making a filing, providing
copies of all such documents to the non-filing party and

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">its advisors prior to filing and, if
requested, to accept all reasonable additions, deletions or changes suggested in connection
therewith) and in connection with obtaining any requisite approvals, consents, orders, exemptions
or waivers by any third party or Governmental Entity; (iii)&nbsp;the satisfaction of the conditions to
the consummation of the Merger set forth in Article&nbsp;VIII; and (iv)&nbsp;the execution of any additional
instruments, including the Certificate of Merger, necessary to consummate the transactions
contemplated hereby. Subject to the terms and conditions of this Agreement and the applicable
provisions of the DGCL, each party hereto agrees to use commercially reasonable efforts to cause
the Effective Time to occur as soon as practicable after the adoption by the stockholders of the
Company of the Merger, this Agreement the other transactions contemplated by this Agreement at the
Stockholders&#146; Meeting. In case at any time after the Effective Time any further action is
necessary to carry out the purposes of this Agreement, the officers and directors of each party
hereto shall use commercially reasonable efforts to take all such necessary action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company and Parent each shall, upon request by the other, furnish the other with all
information concerning itself, its Subsidiaries, directors, officers and stockholders and such
other matters as may be reasonably necessary or advisable in connection with the Proxy Materials or
any other statement, filing, notice or application made by or on behalf of Parent, the Company or
any of their respective Subsidiaries to any third party and/or any Governmental Entity in
connection with the Merger and the transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Subject to applicable Law, the Company and Parent each shall promptly furnish the other
with copies of notices or other communications between Parent or the Company, as the case may be,
or any of their respective Subsidiaries, and any Governmental Entity with respect to such
transactions. The Company shall give prompt notice to Parent of (i)&nbsp;any written communication from
(x)&nbsp;any Governmental Entity and (y)&nbsp;any counterparty to any Significant Contract that alone, or
together with all other Significant Contracts with respect to which such written communication is
received, is material to the Company and its Subsidiaries, taken as a whole, alleging that the
consent of such party is or may be required in connection with the transactions contemplated by
this Agreement (and the responses thereto from the Company, its Subsidiaries or its
Representatives), (ii)&nbsp;any written communication from any Governmental Entity in connection with
the transactions contemplated by this Agreement (and the responses thereto from the Company, its
Subsidiaries or its Representatives), (iii)&nbsp;any Action commenced against or otherwise affecting the
Company or any of its Subsidiaries that are related to the transactions contemplated by this
Agreement (and the response thereto from the Company, its Subsidiaries or its Representatives), or
(iv)&nbsp;any failure of any condition to Parent&#146;s obligations to effect the Merger, and Parent shall
give prompt notice to the Company of any change, fact or condition that is reasonably likely to
result in a failure of any condition to the Company&#146;s obligation to effect the Merger. No party
hereto shall independently participate in any meeting, or engage in any substantive conversation,
with any Governmental Entity with respect to the transactions contemplated hereby without giving
the other party hereto prior notice of the meeting and, to the extent permitted by such
Governmental Entity, the opportunity to attend and/or participate. The parties hereto shall
consult and cooperate with one another in connection with any analyses, appearances, presentations,
memoranda, briefs, arguments, opinions and proposals made or submitted to any Governmental Entity
by or on behalf of any party hereto in connection with the transactions contemplated hereby.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5. <U>Access</U>. Subject to applicable Laws relating to the sharing of information, upon
reasonable notice, the Company shall, and shall cause its Subsidiaries to, afford Parent, and its
officers, employees, counsel, accountants and other authorized Representatives, reasonable access,
during normal business hours throughout the period prior to the Effective Time, to its properties,
books, contracts and records and, during such period, the Company shall, and shall cause its
Subsidiaries to, furnish promptly to Parent all information concerning its business, properties and
personnel as may reasonably be requested. At the request of Parent, throughout the period prior to
the Effective Time, the Company shall use its commercially reasonable efforts to obtain waivers
from Persons who are parties to Contracts with the Company or its Subsidiaries that contain
confidentiality provisions in order for Parent to be provided reasonable access to such Contracts.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6. <U>Consents</U>. Subject to other provisions contained in this Agreement, Parent,
Merger Sub and the Company each will use commercially reasonable efforts to obtain consents of all
third parties and Governmental Entities necessary, proper or advisable for the consummation of the
transactions contemplated hereby; provided, however, that without the prior written consent of
Parent, the Company and its Subsidiaries may not pay or commit to pay any material amount of cash
or other consideration, or incur or commit to incur any material liability or other obligation, in
connection with obtaining such consent, approval or waiver.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7. <U>Public Announcements</U>. The initial press release regarding the Merger shall be a
joint press release mutually agreed upon, and thereafter Parent and the Company will consult with
one another before issuing any press release or otherwise making any public statements with respect
to the transactions contemplated hereby, including the Merger, and shall not issue any such press
release or make any such public statement prior to such consultation, except as may be required by
applicable Law or by obligations pursuant to any listing agreement with any national securities
exchange or the NASDAQ Global Market, as determined in good faith by such party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8. <U>Employee Benefits</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Parent agrees that it shall cause the Surviving Corporation to honor each Benefit Plan in
accordance with its terms as in effect immediately before the Effective Time, subject to any
amendment or termination thereof that may be permitted by such terms. For a period from the
Effective Time through at least one (1)&nbsp;year from Closing, Parent shall provide, or shall cause to
be provided, to those individuals who as of the Effective Time were employees (other than employees
subject to collective bargaining agreements) of the Company and its Subsidiaries (the &#147;<U>Affected
Employees</U>&#148;) pension, health, life insurance, disability and vacation benefits (the
&#147;<U>Employee Plan Benefits</U>&#148;) that are no less favorable in the aggregate to those Employee
Plan Benefits provided to the Affected Employees immediately before the Effective Time.
Notwithstanding the foregoing, but subject to Section&nbsp;7.8(c), nothing contained herein shall
obligate Parent, the Surviving Corporation or any of their affiliates to maintain any particular
Benefit Plan or retain the employment of any Affected Employee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Affected Employee shall receive credit for his or her service with the Company and
its Subsidiaries (and their respective predecessors) before the Effective Time under the employee
benefit plans of Parent and its affiliates (other than the Company and its

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Subsidiaries) providing
Employee Plan Benefits to any Affected Employees after the Effective Time (the &#147;<U>New Plans</U>&#148;)
for purposes of eligibility, vesting and benefit accrual to the same extent as such Affected
Employee was entitled, before the Effective Time, to credit for such service under any comparable
Benefit Plans (except to the extent such credit would result in a duplication of accrual of
benefits); provided that, notwithstanding the forgoing, such service shall only be recognized to
the extent the service would be recognized under the New Plan had the service been performed at the
Parent; and <U>provided further</U> that (i)&nbsp;with respect to any pension plan, such service credit
will only be recognized by the Parent for purposes of vesting and not for purposes of benefit
accrual or early retirement subsidies; and (ii)&nbsp;with respect to retiree health benefits, such
service credit will only be recognized for service performed past the age of forty (40). In
addition, and without limiting the generality of the foregoing: (i)&nbsp;at the Effective Time, each
Affected Employee immediately shall be eligible to participate, without any waiting time, in any
and all New Plans to the extent coverage under such New Plan replaces coverage under a similar or
comparable Company Benefit Plans in which such Affected Employee participated immediately before
the Effective Time to the extent permissible by any applicable insurance carrier or vendor; (ii)
with respect to the calendar year in which the Effective Time occurs, for purposes of each New Plan
providing welfare benefits to any Affected Employee, Parent shall cause all pre-existing condition
exclusions of such New Plan to be waived for such Affected Employee and his or her covered
dependents; and (iii)&nbsp;each Affected
Employee and their eligible dependents shall receive credit for the plan year in which the
Effective Time (or commencement of participation in a New Plan) occurs towards applicable
deductibles and annual out-of-pocket limits for expenses incurred prior to the Effective Time (or
the date of commencement of participation in a New Plan).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Not later than five business days prior to the Stockholders&#146; Meeting, Company shall adopt
a severance plan consistent with the terms set forth in Section&nbsp;7.8(c) of the Company Disclosure
Schedule for the benefit of the Affected Employees. Parent agrees that it shall maintain, or cause
to be maintained, such severance plan for a period of two years following the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company shall take all actions necessary to ensure that all Company Stock Options that
the Company or its Subsidiaries are obligated to grant, as of the date hereof, to any employee,
consultant or director of the Company or any of its Subsidiaries at any time after the date hereof
shall be fully granted to such employee, consultant or director prior to the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;With respect to the ESPP, the Company shall take all actions necessary such that no more
than 20,000 shares of Common Stock may be issued in the aggregate in any individual Offering Period
that begins after the date hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Without limiting the generality of Section&nbsp;10.8, nothing herein expressed or implied shall
confer upon any current or former employee of the Company or any of its Subsidiaries or upon any
representative of any such person, or upon any collective bargaining agent, any rights or remedies,
including any third party beneficiary rights or any right to employment or continued employment for
any specified period, of any nature or kind whatsoever under or by reason of this Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9. <U>Indemnification; Directors&#146; and Officers&#146; Insurance</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The indemnification, advancement and exculpation provisions of the Company&#146;s Amended and
Restated Certificate of Incorporation, the Company&#146;s Amended and Restated Bylaws and those certain
Indemnification Agreements by and among the Company and its directors and certain executive
officers, as in effect at the Effective Time shall not be amended, repealed or otherwise modified
for a period of six (6)&nbsp;years from the Effective Time in any manner that would adversely affect the
rights thereunder of individuals who at the Effective Time were directors, officers or employees of
the Company. Parent shall cause the Surviving Corporation to comply with all such indemnification,
advancement and exculpation provisions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Surviving Corporation shall and Parent shall cause the Surviving Corporation to
maintain the Company&#146;s and its Subsidiaries&#146; existing directors&#146; and officers&#146; liability insurance
(including for acts or omissions occurring in connection with this Agreement and the consummation
of the transactions contemplated hereby) covering each Person covered as of the Effective Time by
the Company&#146;s officers&#146; and directors&#146; liability insurance policy (each such Person, an
&#147;<U>Indemnified Party</U>&#148;) on terms with respect to coverage and amount no less favorable than
those of such policy in effect on the date hereof for a period of six (6)&nbsp;years after the Effective
Time; <U>provided</U>, <U>however</U>, that, subject to the
immediately succeeding sentence, in no event shall the Surviving Corporation be required to
expend in any one (1)&nbsp;year an amount in excess of 250% of the current annual premium paid by the
Company for such insurance (such 250% amount, the &#147;<U>Maximum Annual Premium</U>&#148;);
<U>provided</U>, <U>further</U>, that if the annual premiums of such insurance coverage exceed
such amount, the Surviving Corporation shall be obligated to obtain a policy with the greatest
coverage available for a cost not exceeding the Maximum Annual Premium. In addition, the Company
may and, at Parent&#146;s request, the Company will, purchase a six (6)-year &#147;tail&#148; prepaid policy prior
to the Effective Time on terms and conditions no less advantageous to the Indemnified Parties than
the existing directors&#146; and officers&#146; liability insurance maintained by the Company; provided, that
the amount paid by the Company shall not exceed three times the Maximum Annual Premium. If such
&#147;tail&#148; prepaid policies have been obtained by the Company prior to the Closing, the Surviving
Corporation shall, and Parent shall cause the Surviving Corporation to, maintain such policies in
full force and effect, and continue to honor the respective obligations thereunder, and all other
obligations under this Section&nbsp;7.9(b) shall terminate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If Parent, the Surviving Company or any of their respective successors or assigns 1)
consolidates with or merges into any other Person and shall not be the continuing or surviving
company or entity of such consolidation or merger, or 2) transfers or conveys all or substantially
all of its properties and assets to any Person, then the obligations of Parent or the Surviving
Company, as the case may be, that are set forth under this Section&nbsp;7.9 shall survive, and to the
extent necessary, proper provision shall be made so that the successors and assigns of Parent or
the Surviving Company, as the case may be, shall assume the obligations set forth in this Section
7.9. Parent shall be responsible for any breach by the Surviving Company of the provisions of this
Section&nbsp;7.9.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The provisions of this Section&nbsp;7.9 are intended to be for the benefit of, and shall be
enforceable by, each of the Indemnified Parties and their heirs and legal representatives.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.10. <U>Takeover Statutes</U>. If any Takeover Statute is or may become applicable to the
Merger or the other transactions contemplated by this Agreement, the Company and the Company Board
(or any other appropriate committee of the Company Board) shall grant all approvals and use their
commercially reasonable efforts to take all actions as are necessary so that such transactions may
be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise
act to eliminate or minimize the effects of such Takeover Statute on such transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.11. <U>Rights Plan</U>. The Company Board shall take all further action (in addition to
that referred to in Section&nbsp;5.23) reasonably requested by Parent in order to render the Rights
issued pursuant to the Rights Agreement inapplicable to the Merger and the other transactions
contemplated by this Agreement. Except as provided above with respect to the Merger and the other
transactions contemplated by this Agreement, the Company Board shall not, without the prior written
consent of Parent, (a)&nbsp;amend the Rights Agreement or (b)&nbsp;take any action with respect to, or make
any determination under, the Rights Agreement, including a redemption of the Rights, to facilitate
an Acquisition Proposal in any manner adverse to Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.12. <U>Confidentiality</U>. Parent, Merger Sub and the Company hereby acknowledge that
Parent and the Company have previously executed a Confidentiality Agreement, dated as of March&nbsp;28,
2006, as amended (the &#147;<U>Confidentiality Agreement</U>&#148;), which will continue in full force and
effect in accordance with its terms.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.13. <U>Resignations</U>. To the extent requested by Parent in writing prior to the
Closing, on the Closing Date, the Company shall use commercially reasonable efforts to cause to be
delivered to Parent duly signed resignations, effective as of the Effective Time, of the directors
of the Company and the Subsidiaries designated by Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.14. <U>Stockholder Litigation</U>. The Company shall give Parent the opportunity to
participate in the defense or settlement of any stockholder litigation against the Company and/or
its directors relating to the transactions contemplated hereby, and no such litigation shall be
settled without Parent&#146;s prior written consent.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Conditions to Merger</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1. <U>Conditions to the Obligations of the Company, Parent and Merger Sub to Effect the
Merger</U>. The respective obligation of each of the Company, Parent and Merger Sub to effect the
Merger is subject to the satisfaction or waiver at or prior to the Closing of each of the following
conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Stockholder Approval</U>. This Agreement and the transactions contemplated hereby,
including the Merger, shall have been duly adopted by holders of shares of Common Stock
constituting the Company Requisite Vote in accordance with applicable Law and the Company&#146;s Amended
and Restated Certificate of Incorporation and Amended and Restated Bylaws.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Regulatory Consents</U>. (i)&nbsp;The waiting period applicable to the consummation of
the Merger under the HSR Act shall have expired or been earlier terminated and (ii)&nbsp;all other
governmental consents listed on <U>Section&nbsp;8.1(b)</U> of the Company Disclosure Schedule required
to be obtained prior to the Effective Time by the Company or Parent or any of their respective
Subsidiaries shall have been obtained and shall remain in full force and effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>No Injunction</U>. No court or other Governmental Entity of competent jurisdiction
shall have enacted, issued, promulgated, enforced or entered any Law, rule, regulation, judgment,
determination, decree, injunction or other order that is in effect and restrains, enjoins or
otherwise prohibits consummation of the Merger or the other transactions contemplated by this
Agreement (collectively, an &#147;<U>Injunction</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2. <U>Conditions to Obligations of Parent and Merger Sub</U>. The obligation of Parent and
Merger Sub to effect the Merger is also subject to the satisfaction or waiver by Parent at or prior
to the Closing of the following conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Representations and Warranties</U>. The representations and warranties of the
Company contained in Section&nbsp;5.2 (<U>Capitalization of the Company and its Subsidiaries)</U> shall
be true and correct in all respects except for such inaccuracies as are de minimis in the aggregate
(A)&nbsp;on the date of this Agreement and (B)&nbsp;at and as of the Closing Date with the same force and
effect as if made as of such date (except to the extent that such representation and warranty
speaks as of a particular date, in which case such representation and warranty shall be true and
correct in all material respects as of such earlier date). All other representations and
warranties of the Company contained in Article&nbsp;V shall be true and correct in each case (A)&nbsp;on the
date of this Agreement and (B)&nbsp;at and as of the Closing Date with the same force and effect as if
made as of such date (except to the extent that such representation and warranty speaks as of a
particular date, in which case such representation and warranty shall be true and correct in all
respects as of such earlier date), except for failures of such representations and warranties to be
true and correct that have not had, and would not reasonably be expected to have, individually or
in the aggregate, a Company Material Adverse Effect (it being understood that for purposes of
determining the accuracy of the representations and warranties described in this sentence, all
materiality and Company Material Adverse Effect qualifications contained in such representations
and warranties shall be disregarded); and Parent shall have received at the Closing a certificate
signed on behalf of the Company by a senior executive officer of the Company to the effect that the
conditions set forth in this Section&nbsp;8.2 have been satisfied.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Performance of Obligations of the Company</U>. The Company shall have performed in
all material respects the agreements and obligations required to be performed by it under this
Agreement at or prior to the Closing Date, and Parent shall have received a certificate signed on
behalf of the Company by a senior executive officer of the Company to the effect that the condition
set forth in this Section&nbsp;8.2(b) has been satisfied.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Company Material Adverse Effect</U>. Except as set forth in the Company Disclosure
Schedule, since the date of this Agreement, there shall not have been any Company Material Adverse
Effect or any event, state of fact, circumstance, development, change or effect that would,
individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3. <U>Conditions to Obligation of the Company</U>. The obligation of the Company to effect
the Merger is also subject to the satisfaction or waiver by the Company at or prior to the
Effective Time of the following conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Representations and Warranties</U>. The representations and warranties of Parent and
Merger Sub set forth in this Agreement shall be true and correct in all material respects on the
Closing Date with the same effect as though such representations and warranties had been made on
and as of the Closing Date (except to the extent that any such representation and warranty
expressly speaks as of an earlier date, in which case such representation and warranty shall be
true and correct as of such earlier date) and the Company shall have received at the Closing a
certificate signed on behalf of each of Parent and Merger Sub by a senior executive officer of each
to the effect that the condition set forth in this Section&nbsp;8.3(a) has been satisfied.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Performance of Obligations of Parent and Merger Sub</U>. Each of Parent and Merger
Sub shall have performed in all material respects the agreements and obligations
required to be performed by it under this Agreement at or prior to the Closing Date, and the
Company shall have received a certificate signed on behalf of each of Parent and Merger Sub by a
senior executive officer of each to the effect that the condition set forth in this Section&nbsp;8.3(b)
has been satisfied.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Termination</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1. <U>Termination by Mutual Consent</U>. This Agreement may be terminated and the Merger
may be abandoned at any time prior to the Effective Time, whether before or after the adoption by
the stockholders of the Company referred to in Section&nbsp;8.1(a), by mutual written consent of the
Company and Parent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2. <U>Termination by Either Parent or the Company</U>. This Agreement may be terminated
and the Merger may be abandoned at any time prior to the Effective Time by Parent or by the Company
if (a)&nbsp;the Merger shall not have been consummated by June&nbsp;30, 2007 (the &#147;<U>Termination
Date</U>&#148;); (b)&nbsp;the adoption by the Company&#146;s stockholders required by Section&nbsp;8.1(a) shall not
have been obtained at the Stockholders&#146; Meeting (after giving effect to all adjournments or
postponements thereof); or (c)&nbsp;any Injunction permanently restraining, enjoining or otherwise
prohibiting consummation of the Merger shall become final and non-appealable; <U>provided</U>,
that the right to terminate this Agreement pursuant to Section&nbsp;9.2(a) shall not be available to any
party if the circumstances described in Section&nbsp;9.2(a) were caused by such party&#146;s failure to
comply with its obligations under this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3. <U>Termination by the Company</U>. This Agreement may be terminated and the Merger may
be abandoned at any time, but, in the case of clause (a)&nbsp;below, only prior to the adoption by
stockholders of the Company referred to in Section&nbsp;8.1(a), by action of the Company Board (a)(i) if
the Company Board shall have withdrawn, qualified or changed the Recommendation in a manner adverse
to Parent and in favor of a Superior Proposal in the manner provided for in, and in compliance
with, Section&nbsp;7.2 (including, without limitation the right of Parent to propose revisions to the
terms of this Agreement) and (ii)&nbsp;contemporaneously

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with such termination, the Company enters into
a definitive acquisition, merger or similar agreement to effect the Superior Proposal and (iii)
contemporaneously therewith, the Company pays to Parent the amount specified in Section&nbsp;9.5(b); or
(b)&nbsp;if there has been a breach of any representations, warranties, covenants or agreements made by
Parent or Merger Sub in this Agreement, or any such representations and warranties shall have
become untrue or incorrect after the execution of this Agreement, such that (i)&nbsp;the condition set
forth in either Section&nbsp;8.3(a) or 8.3(b) would not be satisfied and (ii)&nbsp;such breach or failure to
be true and correct is not cured within 20 business days following receipt of written notice of
such breach or failure from Company; provided, however, that the failure of any such condition to
be capable of satisfaction is not the result of a material breach of this Agreement by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4. <U>Termination by Parent</U>. This Agreement may be terminated and the Merger may be
abandoned at any time prior to the Effective Time by action of the Board of Directors of Parent
(a)(i) if the Company Board shall have withdrawn, modified, qualified or changed the Recommendation
in a manner adverse to Parent or (ii)&nbsp;if the Company Board
approves, endorses or recommends any Acquisition Proposal other than the Merger or (iii)&nbsp;if
the Company or the Company Board resolves or announces its intention to do any of the foregoing, in
the case of any of (i), (ii)&nbsp;or (iii)&nbsp;whether or not permitted by Section&nbsp;7.2; (b)&nbsp;if the Company
(i)&nbsp;materially breaches its obligations under Section&nbsp;7.2 or 7.3(b), or the Company Board or any
committee thereof shall resolve to do any of the foregoing, or (ii)&nbsp;materially breaches its
obligations under Section&nbsp;7.3(a) and such breach is not cured within 10&nbsp;days after the Company&#146;s
receipt of written notice asserting such breach or failure from Parent; or (c)&nbsp;if there has been a
breach of any other representation, warranty, covenant or agreement made by the Company in this
Agreement, or any such representation and warranty shall have become untrue or incorrect after the
execution of this Agreement, such that (i)&nbsp;the condition set forth in either Section&nbsp;8.2(a) or
8.2(b) would not be satisfied and (ii)&nbsp;such breach or failure to be true or correct is not cured
within 20 business days following receipt of written notice of such breach or failure from Parent;
provided, however, that the failure of any such condition to be capable of satisfaction is not the
result of a material breach of this Agreement by Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5. <U>Effect of Termination and Abandonment; Termination Fee</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the event of a termination of this Agreement and the abandonment of the Merger pursuant
to this Article&nbsp;IX, this Agreement (other than the Company&#146;s obligation pursuant to Section&nbsp;9.5(b),
if applicable and Article&nbsp;X), shall become void and of no effect with no liability on the part of
any party hereto (or of any of its directors, officers, employees, agents, legal and financial
advisors or other representatives); <U>provided</U>, <U>however</U>, that, no such termination
shall relieve any party hereto of any liability or damages resulting from any willful or
intentional breach of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In the event that (i)&nbsp;this Agreement is terminated by the Company pursuant to Section
9.3(a) or Parent pursuant to Section&nbsp;9.4(a) or 9.4(b) or (ii)&nbsp;this Agreement is terminated by the
Company or Parent pursuant to Section&nbsp;9.2(a) or 9.2(b) and (x)&nbsp;an Acquisition Proposal (but
substituting &#147;50%&#148; for &#147;15%&#148; in the definition of such term) (an &#147;<U>Alternative Transaction</U>&#148;)
shall have been made public and not been withdrawn prior to the time of the Stockholders&#146; Meeting
(or at any adjournment thereof), and (y)&nbsp;the Company enters into a definitive agreement with
respect to any Alternative Transaction within 12&nbsp;months from the date

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of such termination or an
Alternative Transaction is consummated within 12&nbsp;months from the date of such termination, then in
the case of either of the foregoing subclauses (i)&nbsp;or (ii)&nbsp;the Company shall pay Parent (A)
simultaneously with such termination in the event of a termination by the Company described in
clause (b)(i), (B)&nbsp;on the second business day following termination by Parent described under
clause (b)(i) and (C)&nbsp;upon such fee becoming payable under clause (b)(ii), by wire transfer of same
day funds, a fee equal to $42,100,000 (the &#147;<U>Termination Fee</U>&#148;); <U>provided</U>,
<U>however</U>, that, in the event that (1)&nbsp;this Agreement is terminated pursuant to Section
9.2(a) and an Alternative Transaction is subsequently consummated with or a definitive agreement
with respect to an Alternative Transaction is subsequently entered into during the twelve-month
period following termination with a Person other than the Person making the Alternative Transaction
at the time of such termination and (2)&nbsp;the consideration per share of Common Stock to be paid in
such Alternative Transaction is less than the Merger Consideration, then the Termination Fee will
be discounted in the same proportion as the consideration to be paid in the Alternative Transaction
is less than the Merger Consideration. For purposes of this Section&nbsp;9.2(b)(iii), the &#147;consideration
per share of
Common Stock&#148; shall be determined as follows: (x)&nbsp;if the consideration consists of cash, such
amount of cash, (y)&nbsp;if the consideration consists of marketable securities, the value of such
marketable securities at the close of business on the day before the date such Alternative
Transaction is consummated or a definitive agreement with respect to such Alternative Transaction
is entered into, as the case may be, and (z)&nbsp;if the consideration is in a form other than cash or
marketable securities, such value as the parties shall reasonably agree.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Miscellaneous and General</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1. <U>Non-Survival of Representations and Warranties and Agreements</U>. None of the
representations and warranties in this Agreement or in any instrument delivered pursuant to this
Agreement shall survive the Effective Time or, except as set forth in Section&nbsp;9.5 hereof, the
termination of this Agreement pursuant to the terms hereof. This Section&nbsp;10.1 shall not limit any
covenant or agreement of the parties which by its terms contemplates performance after the
Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2. <U>Modification or Amendment</U>. Subject to the provisions of applicable Law, at any
time prior to the Effective Time, (i)&nbsp;this Agreement may be amended, modified or supplemented only
in writing executed by each of the parties hereto by action of the Board of Directors of each such
party (whether before or after the Company Requisite Vote) and (ii)&nbsp;any provisions herein may be
waived only in writing executed by the party or parties against whom such waiver is asserted by
action of such party or parties&#146; Board of Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3. <U>Waiver of Conditions</U>. The conditions to each of the parties&#146; obligations to
consummate the Merger are for the sole benefit of such party and may be waived by such party in
whole or in part to the extent permitted by applicable Law, in such party&#146;s sole discretion.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4. <U>Counterparts; Signatures</U>. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original but all of which together shall be

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">considered one and the same agreement and shall become effective when counterparts have been signed
by each of the parties hereto and delivered to the other parties, it being understood that all
parties need not sign the same counterpart. This Agreement may be executed and delivered by
facsimile transmission.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.5. <U><B>GOVERNING LAW AND VENUE; WAIVER OF JURY TRIAL</B></U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <B>THIS AGREEMENT SHALL BE DEEMED TO BE MADE IN AND IN ALL RESPECTS SHALL BE INTERPRETED,
CONSTRUED AND GOVERNED BY AND IN ACCORDANCE WITH THE LAW OF THE STATE OF DELAWARE WITHOUT REGARD TO
THE CONFLICT OF LAW PRINCIPLES THEREOF. </B>The parties hereto hereby irrevocably submit exclusively
to the jurisdiction of the Court of Chancery of the State of Delaware and the Federal courts of the
United States of America located in the State of Delaware solely in respect of the interpretation
and enforcement of the provisions of this Agreement and of the documents referred to in this
Agreement, and in respect of the transactions
contemplated hereby, and hereby waive, and agree not to assert, as a defense in any action,
suit or proceeding for the interpretation or enforcement hereof or of any such document, that it is
not subject thereto or that such action, suit or proceeding may not be brought or is not
maintainable in said courts or that the venue thereof may not be appropriate or that this Agreement
or any such document may not be enforced in or by such courts, and the parties hereto irrevocably
agree that all claims with respect to such action or proceeding shall be heard and determined in
such a Delaware State or Federal court. The parties hereto hereby consent to and grant any such
court jurisdiction over the person of such parties for purposes of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY
HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR
THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i)&nbsp;NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (ii)
EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER; (iii)&nbsp;EACH PARTY MAKES
THIS WAIVER VOLUNTARILY; AND (iv)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY,
AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.5.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.6. <U>Notices</U>. Any notice, request, instruction or other document to be given
hereunder by any party to the others shall be in writing and delivered personally or sent by
registered or certified mail, postage prepaid, facsimile or by overnight courier:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">If to Parent or Merger Sub:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Merck &#038; Co., Inc.<BR>
One Merck Drive<BR>
P.O. Box 100, WS3A-65<BR>
Whitehouse Station, New Jersey 08889-0100<BR>
Attention: Office of the Secretary<BR>
Facsimile: (908)&nbsp;735-1246
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">with a copy, which will not constitute notice, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Fried, Frank, Harris, Shriver &#038; Jacobson LLP<BR>
One New York Plaza<BR>
New York, New York 10004<BR>
Attention: David N. Shine/Brian T. Mangino<BR>
Facsimile: (212)&nbsp;859-4000
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">If to the Company:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Sirna Therapeutics, Inc.<BR>
185 Berry Street, Suite&nbsp;6504<BR>
San Francisco, California 94107<BR>
Attention: President &#038; CEO<BR>
Facsimile: (415)&nbsp;512-7022
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">With a copy to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Sirna Therapeutics, Inc.<BR>
185 Berry Street, Suite&nbsp;6504<BR>
San Francisco, California 94107<BR>
Attention: Vice President of Legal Affairs<BR>
Facsimile: (415)&nbsp;512-7022
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">with a copy, which will not constitute notice, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">O&#146;Melveny &#038; Myers LLP<BR>
2765 Sand Hill Road<BR>
Menlo Park, California 94025<BR>
Attention: Michael J. Kennedy/Sam Zucker<BR>
Facsimile: (650)&nbsp;473-2601
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or to such other persons or addresses as may be designated in writing by the Person to receive such
notice as provided above. Any notice, request, instruction or other document given as provided
above shall be deemed given to the receiving party upon actual receipt, if delivered personally;
three (3)&nbsp;business days after deposit in the mail, if sent by registered or certified mail; upon
confirmation of successful transmission if sent by facsimile; or on the next business day after
deposit with an internationally recognized overnight courier, if sent by such a courier.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.7. <U>Entire Agreement</U>. This Agreement, together with the schedules and Annexes
hereto, and the Confidentiality Agreement and Voting Agreements constitute the entire agreement
among the parties hereto with respect to the subject matter hereof and supersedes all other prior
agreements and understandings, both written and oral, between the parties with respect to the
subject matter hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.8. <U>No Third Party Beneficiaries</U>. Except as expressly set forth in Section&nbsp;7.9
(Indemnification; Directors&#146; and Officers&#146; Insurance) of this Agreement, this Agreement is not
intended to, and does not, confer upon any Person other than the parties who are signatories hereto
any rights or remedies hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.9. <U>Severability</U>. The provisions of this Agreement shall be deemed severable and
the invalidity or unenforceability of any provision shall not affect the validity or enforceability
of the other provisions hereof. If any provision of this Agreement, or the application thereof to
any Person or any circumstance is determined by a court of competent jurisdiction to be invalid,
void or unenforceable the remaining provisions hereof, shall, subject to the following sentence,
remain in full force and effect and shall in no way be affected, impaired
or invalidated thereby, so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner adverse to either party. Upon such
determination, the parties shall negotiate in good faith in an effort to agree upon such a suitable
and equitable provision to effect the original intent of the parties.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.10. <U>Interpretation; Absence of Presumption</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;For the purposes hereof, (1)&nbsp;words in the singular shall be held to include the plural and
<I>vice versa </I>and words of one gender shall be held to include the other gender as the context
requires; (2)&nbsp;the terms &#147;<U>hereof</U>,&#148; &#147;<U>herein</U>,&#148; and &#147;<U>herewith</U>&#148; and words of
similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole
(including the schedules and annexes hereto) and not to any particular provision of this Agreement,
and Article, Section, paragraph, Schedule and Annex references are to the Articles, Sections,
paragraphs, Schedules and Annexes to this Agreement unless otherwise specified; (3)&nbsp;the word
&#147;<U>including</U>&#148; and words of similar import when used in this Agreement shall mean
&#147;<U>including without limitation</U>&#148; unless the context otherwise requires or unless otherwise
specified; (4)&nbsp;the word &#147;<U>or</U>&#148; shall not be exclusive; (5)&nbsp;provisions shall apply, when
appropriate, to successive events and transactions; and (6)&nbsp;all references to any period of days
shall be deemed to be to the relevant number of calendar days unless otherwise specified.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The parties have participated jointly in negotiating and drafting this Agreement. In the
event that an ambiguity or a question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.11. <U>Expenses</U>. Except as otherwise provided in Section&nbsp;9.5, whether or not the
Merger is consummated, all costs and expenses incurred in connection with this Agreement and the
Merger and the other transactions contemplated by this Agreement shall be paid by the party
incurring such expense.
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.12. <U>Assignment</U>. This Agreement shall not be assignable by any party hereto;
<U>provided</U>, <U>however</U>, that Parent may designate, by written notice to the Company,
another Subsidiary of Parent to be a constituent corporation in lieu of Merger Sub, whereupon all
references herein to Merger Sub shall be deemed references to such other Subsidiary, except that
all representations and warranties with respect to Merger Sub as of the date of this Agreement
shall be deemed representations and warranties with respect to such other Subsidiary as of the date
of such designation. Any purported assignment in violation of this Agreement will be void <I>ab
initio</I>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.13. <U>Attorneys&#146; Fees</U><B>. </B>In any action at law or suit in equity to enforce this
Agreement or the rights of any of the parties hereunder, the prevailing party in such action or
suit shall be entitled to receive a reasonable sum for its attorneys&#146; fees and all other reasonable
costs and expenses incurred in such action or suit.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.14. <U>Certain Definitions</U>. The following terms, as used herein, have the meanings
which meanings shall be applicable equally to the singular and plural of the terms defined:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;an &#147;<U>Affiliate</U>&#148; of any Person means another person that directly or indirectly,
through one or more intermediaries, controls, is controlled by, or is under common control with,
such first Person, where &#147;control&#148; means the possession, directly or indirectly, of the power to
direct or cause the direction of the management policies of a Person, whether through the ownership
of voting securities, by contract, as trustee or executor, or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<U>Company Material Adverse Effect</U>&#148; means any change or effect, event, violation,
circumstance, occurrence, state of facts or development (any such item, an &#147;<U>Effect</U>&#148;) that,
(i)&nbsp;is materially adverse to the business, assets, results of operations or financial condition of
the Company and its Subsidiaries, taken as a whole, or (ii)&nbsp;would prevent or delay beyond the
Termination Date the consummation by the Company of the transactions contemplated hereby; provided
that no Effect related to or arising out of any of the following shall be taken into account in
determining whether there may exist a Company Material Adverse Effect: (A)&nbsp;circumstances
generally affecting the biotechnology industry (which changes or developments, in each case, do not
materially disproportionately affect the Company and its Subsidiaries taken as a whole); (B)
changes affecting the United States economy in general (which changes or developments, in each
case, do not materially disproportionately affect the Company and its Subsidiaries taken as a
whole) or the financial or securities markets in general, political instability or political
conditions in the United States or any acts of terrorism, military actions or war or other national
calamity directly involving the United States; (C)&nbsp;other than with respect to Section&nbsp;5.4
(<U>Consents and Approvals; No Violations</U>), the announcement or pendency of this Agreement or
actions pursuant to (or required by) this Agreement; (D)&nbsp;any change in the Company&#146;s stock price or
trading volume (it being understood that any change in the Company underlying or contributing to
such change in stock price or trading volume may be taken into account in determining whether there
exists a Company Material Adverse Effect); (E)&nbsp;any determination by, or delay of a determination
by, or delay of a submission to, the FDA or its European equivalent, or any panel or advisory body
empowered or appointed thereby; (F)&nbsp;the failure by the Company to meet any internal or published
projections, forecasts or revenue or earnings predictions for any period (it being understood that
any change in the Company

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">underlying or contributing to such failure may be taken into account in
determining whether there exists a Company Material Adverse Effect); (G)&nbsp;any changes in applicable
Law or GAAP (which changes, in each case, do not materially disproportionately affect the Company
and its Subsidiaries taken as a whole); or (H)&nbsp;any effect resulting from the actions of Parent or
any of its affiliates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) &#147;<U>Knowledge</U>&#148; shall mean, with respect to a party hereto, and with respect to any
matter in question, that any executive officer of such party has actual knowledge of such matter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) &#147;<U>Lien</U>&#148; means, with respect to any asset (including any security) any option,
claim, mortgage, lien, pledge, charge, security interest or encumbrance or restrictions of any kind
in respect of such asset.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) &#147;<U>Person</U>&#148; shall mean any individual, corporation (including not-for-profit),
general or limited partnership, limited liability company, joint venture, estate, trust,
association, organization, Governmental Entity or other entity of any kind or nature.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) &#147;<U>Subsidiary</U>&#148; shall mean, with respect to any party, any corporation, limited
liability company, partnership or similar entity, whether domestic or foreign to the United States,
of which (x)&nbsp;such party or any other Subsidiary of such party is a general partner or (y)&nbsp;at least
a majority of the securities (or other interests having by their terms ordinary voting power to
elect a majority of the Board of Directors or others performing similar functions with respect to
such corporation or other organization) is, directly or indirectly, owned or controlled by such
party or by any one or more of its Subsidiaries, or by such party and one or more of its
Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) &#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; means all taxes (whether federal, state, local or
foreign) including, without limitation, all income, profits, franchise, gross receipts, stamp,
payroll, employment, use, property, withholding, excise and other taxes, duties or assessments of
any nature whatsoever, together with all interest, penalties and additions imposed with respect to
such amounts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) &#147;<U>Tax Return</U>&#148; means all returns, forms, reports and other documentation required to
be filed with, or supplied to, any federal, state, local or foreign tax authority with respect to
Taxes (and any amendments, supplements and supporting documentation thereto).
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Remainder of Page Intentionally Left Blank&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly authorized
officers of the parties hereto as of the date first written above.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SIRNA THERAPEUTICS, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Howard W. Robin
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Howard W. Robin</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">MERCK &#038; CO., INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Richard T. Clark
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Richard T. Clark</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer and President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SPINNAKER ACQUISITION CORP.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Richard N. Kender
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Richard N. Kender</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
